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OLANZAPINE-INDUCED LIVER INJURY: DIRECT METABOLIC EFFECTS, 
EXACERBATION BY HIGH-FAT DIET, AND PROTECTION WITH 
SULFORAPHANE 
 
Robin H. Schmidt 
07/08/2013 
 
Olanzapine (OLZ) is an effective first-line treatment for schizophrenia and 
bipolar disorder.  The benefits of OLZ are countermanded by side effects such as 
weight gain, glucose intolerance, dyslipidemia, and liver injury.  These effects 
impact not only antipsychotic medication compliance, but also increase the 
health risks to patients.  Most studies to date have focused on potential effects of 
OLZ on the central nervous system (e.g., hypothalamic regulation of satiety); 
however, peripheral changes in key metabolic organs such as the liver may also 
play a critical role.  The obesity rates in the US are now at epidemic levels and 
obesity-induced liver disease (i.e., non-alcoholic fatty liver disease, or NAFLD) is 
on the rise.  It is now understood that obesity is a significant risk factor for a 
myriad of drug-induced liver injuries.  Given that the obesity incidence in the 
psychiatric population is even higher than in the US population as a whole, the 




The purpose of this work was to determine the mechanisms of OLZ-
induced hepatic dysmetabolism, and to test the hypothesis that OLZ enhances 
obesity-induced hepatic injury.  OLZ was administered in a mouse model for four 
weeks along with a high-fat diet (HFD) or low-fat control diet.  OLZ alone 
increased body weight and caused mild glucose intolerance, without a 
commensurate increase in food consumption.  OLZ alone also caused hepatic 
steatosis and injury.  Interestingly, although OLZ increased hepatic triglyceride 
synthesis and storage, it did not increase the synthesis or abundance of hepatic 
free fatty acids.  OLZ administration appeared to cause a pseudo-fasted state 
and dramatically depleted hepatic glycogen reserves.  These effects of OLZ 
occurred in parallel to significant changes in hepatic metabolite profiles.  The 
protein kinases AMPK and mTOR are generally differentially activated, and 
mediate opposing metabolic functions; however, OLZ administration 
simultaneously activated both AMPK and mTOR.  When OLZ and HFD were 
combined, there was an even greater increase in weight gain and glucose 
intolerance.  Liver damage from concurrent HFD and OLZ was worse than liver 
damage resulting from HFD or OLZ alone.   
Lastly, sulforaphane (SFN) was tested as a possible preventive against 
HFD- and OLZ-induced toxicity.  Some mice receiving HFD and OLZ were also 
treated with SFN (90 mg/kg/d).  SFN, a known inducer of the Nrf2 intrinsic 
antioxidant pathway, prevented weight gain and liver injury and rescued hepatic 
glycogen storage.  Furthermore, SFN decreased the presence of 4-




substantially limits oxidative stress in this model. 
In summary, these data show that OLZ dysregulates glucose and lipid 
metabolism and exacerbates hepatic changes caused by HFD exposure.  The 
outcomes of OLZ administration on hepatic metabolism may reflect, in part, the 
contradictory inputs of simultaneous AMPK and mTOR activation. These data 
indicate that the metabolic changes caused by OLZ may sensitize the liver to 
injury caused by HFD and that underlying obesity/liver disease may aggravate 
OLZ-induced side effects.  The activation of intrinsic antioxidant defenses with 
SFN can partially prevent these effects of OLZ and may represent a useful 
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A. Background and rationale for this study 
 Atypical antipsychotics: usage and side effects 1.
Olanzapine (OLZ) is one of the most effective drug options for managing 
the symptoms of schizophrenia and bipolar disorder.1,2  Much like earlier 
antipsychotic drugs (e.g., haloperidol), OLZ and other second generation 
antipsychotic medications bind antagonistically at dopamine receptors.3  Unlike 
the earlier antipsychotic medications, OLZ binds and antagonizes serotonin 
receptors, particularly the 5-HT2C receptor, and has a lower affinity for the D2 
subclass of dopamine receptors.  OLZ’s different affinities for various 
neurotransmitter receptors may explain why it is less likely to cause tardive 
dyskinesia and movement-related side effects than the previous generation of 
drugs.4  Even among second generation antipsychotic drugs, OLZ is preferred for 
its ability to treat psychiatric symptoms,5,6 and in contrast to the chemically-
related clozapine, there is little or no risk of developing blood disorders.7  These 
attributes make OLZ a drug of choice to treat severe mental illness.  Indeed, the 
lack of debilitating side effects has advanced the off-label use of the drug for 




Although OLZ does not share the severe toxicity of its first-generation 
predecessors, it does have side effects that limit its therapeutic potential.  
Numerous studies show that OLZ causes substantial and reproducible weight 
gain.10-12  Though exact figures vary, a meta-analysis conducted by Allison et al. 
found a mean weight gain of 4.0 kg after 10 weeks of OLZ administration.13  
Weight gain with OLZ does not usually reach a rapid plateau, but rather 
continues gradually throughout the years of treatment.10  Prescribing information 
for Zyprexa, the brand-name formulation of OLZ,  reports that the percent of adult 
patients with weight gain >15kg was 4.3% after 6 months of OLZ administration, 
14.1% after 12 months, 17.9% after 24 months and 22.5% after 36 months.14,15  
Side effects such as weight gain are additionally correlated with decreased 
treatment compliance.16,17  Overall, approximately 58% of patients requiring 
antipsychotic medication do not adhere to treatment plans,18 leading to relapse 
and increasing the need for costly inpatient psychiatric hospital stays.19,20 
 Overweight, obesity, and liver injury 2.
Obesity is a major cause of preventable illness worldwide.21  In the United 
States obesity has reached epidemic proportions, with approximately 68.6% of 
Americans meeting the criteria for overweight (body mass index ≥ 25) and 33.8% 
meeting the criteria for obesity (BMI ≥ 30) according to the most recent National 
Health and Nutrition Examination Survey (NHANES III).22  Importantly, there is an 
upward trend in BMI in the United States: the prevalence of obesity has doubled 
since NHANES data were initially compiled in the 1960s.23   




cardiovascular disease) is non-alcoholic fatty liver disease (NAFLD), which has 
become one of the leading causes of chronic liver disease worldwide.24  NAFLD 
is pathologically similar to alcoholic liver disease (ALD), but is distinguished by its 
development in the absence of significant alcohol consumption.25  Apart from 
obesity the risk factors for primary NAFLD include type II diabetes mellitus and 
dyslipidemia.  Though its features are well-defined, NAFLD is not a single, 
uniform illness.  Instead, it encompasses a spectrum of liver disease states, 
ranging from simple steatosis, to active inflammation (non-alcoholic 
steatohepatitis, or NASH), to advanced fibrosis and cirrhosis,26 and ultimately 
hepatocellular carcinoma.27  Not all those with NAFLD are severely overweight; 
however, the majority of NAFLD patients do have metabolic risk factors such as 
obesity, hyperlipidemia, and/or type 2 diabetes mellitus.28  According to NHANES 
III data, an estimated 32.5 million people – 21.7% of the United States 
noninstitutionalized population between the ages of 20 and 74 – had some 
degree of hepatic steatosis.  Of these individuals, 28.8 million, or 90%, were 
considered by NHANES to have NAFLD.29   
 Olanzapine, obesity, and hepatic metabolism 3.
The side effects of OLZ are particularly relevant at this time, with obesity 
increasing at an alarming rate in the US and other industrialized countries.30  
Moreover, even within an increasingly overweight general population, obesity 
disproportionately affects individuals with severe mental illnesses.31,32  When a 
cohort of randomly selected psychiatric outpatients was compared to a gender-, 




outpatient psychiatric population was nearly double that of the NHANES group.33  
Weight gain is not the only major metabolic effect of antipsychotic administration: 
OLZ has also been associated with liver injury,34 dyslipidemia,35 and insulin 
resistance.11,36  These effects, as mentioned previously, increase overall patient 
mortality37 and strongly negatively influence patient treatment compliance.  It is 
therefore necessary to develop strategies that prevent, minimize, or reverse the 
adverse metabolic effects that occur during OLZ treatment, especially for a 
population already at risk for obesity and its sequelae.  
The purpose of the work described in the chapters that follow was to 
explore the effects of OLZ on indices of carbohydrate and lipid metabolism.  
Ultimately, the goal was to determine relevant mechanisms in the development, 
progression and treatment of OLZ-induced liver injury.  The following hypotheses 
are central to this dissertation: 
B. Aims and proposals 
 Does olanzapine directly alter hepatic energy metabolism? 1.
Hepatic metabolism is paramount to this study for several reasons.  First, 
the liver is indispensable to whole-body glycemic control and lipid regulation.  
The liver acts as a site for glucose uptake and gluconeogenesis, and provides a 
large store of glycogen for the maintenance of blood glucose during fasting.38  
Despite its somewhat small size in proportion to the rest of the body, the liver 
accounts for ~20% of the body’s resting energy expenditure.39  Secondly, 
regardless of whether it is administered orally or parenterally, OLZ reaches high 




Finally, the liver’s role in the development of metabolic side effects may be more 
important than previously thought.  The beneficial effects of OLZ are assumed to 
be mediated at the level of the CNS.  Not surprisingly, most studies into the 
metabolic side effects of OLZ have also focused on the CNS.  Although the CNS 
clearly plays a key role in regulating food consumption, obesity, dyslipidemia and 
diabetes,41-43 recent studies have suggested that the hepatic effects of OLZ 
contribute to the drug’s metabolic disturbances.44  Interestingly, the changes 
induced by OLZ administration in carbohydrate and lipid metabolism may in fact 
precede weight gain, which suggests a potential direct effect of the drug on these 
pathways.36,45  The purpose of the experiments described in Chapter III was to 
determine what direct effects OLZ administration has on the liver, in the absence 
of underlying illness or additional treatment. 
 Can OLZ act as a second “hit” in fatty liver diseases? 2.
As described in the previous section, NAFLD is a spectrum of liver 
diseases spanning from the relatively benign (steatosis) to the most severe (liver 
cancer).27  The prevalence of simple steatosis in individuals at risk for NAFLD 
can be very high; for example, the prevalence in individuals with a body mass 
index (BMI) of 35 or greater has been reported to be 90%.46  In contrast, the 
prevalence of NASH is much lower in this population (~40%).46  These factors 
emphasize that the risk for developing more severe stages of NAFLD (i.e., NASH 
and beyond) is not based solely on obesity, but is rather mitigated by genetic or 
environmental factors – that is, disease progression is governed by the ‘2-hit’ 




changes to liver that are pathologically inert can aggravate the hepatotoxic 
response caused by a second agent.47,48  It is possible that OLZ treatment could 
be such a previously unidentified agent in the progression of NAFLD.  The 
purpose of the experiments described in Chapter IV was to assess the impact of 
OLZ on liver pathology in mice already predisposed to obesity and liver injury. 
 Can Nrf2 activation with sulforaphane protect against OLZ-induced 3.
liver injury? 
The formation of electrophilic and oxidative molecules is an invariable 
consequence of normal metabolism.49  Reactive metabolites are generally 
neutralized and excreted, though they may also serve as intermediates in cell 
signaling.50,51  The oxidant-antioxidant equilibrium is, in most cases, well-
regulated by a series of enzymes specifically evolved for this purpose.  However, 
an excess of oxidant species and/or a lack of antioxidant species will sometimes 
develop, and it is this state of imbalance that is known as oxidative stress.52 
Oxidative stress is not defined as a disease, though it is widely 
hypothesized to be a common mechanism in the initiation or progression of many 
diseases.  Manifestations of oxidative stress such as lipid peroxidation are 
repeatedly observed in conjunction with metabolic diseases.53-56  High levels of 
fatty acids, cholesterol, and glucose produce reactive oxygen species,57-59 and 
may therefore be crucial to the progression from obesity to more serious 
illnesses such as NASH.60,61  It may also follow that the metabolic side effects of 
OLZ can be prevented by antioxidants.  Though the exact involvement of 




recently reported to raise levels of malondialdehyde, a common biomarker for 
oxidative stress.62 
Past research has largely used direct antioxidants (e.g., vitamin C) to 
prevent drug-induced oxidative stress.  This approach has been more 
consistently successful in vitro than in whole organisms.  At worst, direct-acting 
treatments actually induce disturbances in cellular redox status.63-65  A meta-
analysis of clinical trials using vitamin E found that in high doses, vitamin E 
significantly increases all-cause mortality.66  The toxicity of supplements such as 
vitamin E may result from their dual nature: at high doses, many antioxidants act 
as pro-oxidants.67,68  In contrast, indirect agents such as sulforaphane (SFN) 
have neither reducing nor oxidizing capability.69,70  SFN instead works by 
inducing Nrf2, thereby enhancing the cell’s own reducing capability and 
supporting the function of endogenous detoxifying enzymes.71   
There is already some evidence that alleviating oxidative stress can 
alleviate the side effects of OLZ.  Although high-dose vitamin E did not improve 
insulin resistance in OLZ-medicated adults in a small clinical trial conducted by 
Salmasi et al.,72 Shertzer et al. protected mice against OLZ-mediated metabolic 
toxicity with tetrahydroindenoindole, an antioxidant,73 and acetaminophen, which 
functioned as an antioxidant at the dose in which it was given.74  Similarly, a 
study by Mas et al. used SFN to prevent oxidative stress in neuroblastoma cells 
exposed to the second-generation antipsychotic drug risperidone.75  It remains 
possible that oxidative stress is crucial to metabolic side effect development, but 




experiments described in Chapter V was to test Nrf2 induction (via SFN) as a 
strategy against obesity- and OLZ-induced dysregulation of metabolism, 
particularly in the liver. 







A. Animals and treatments 
Female C57BL/6J mice (8 weeks old) were purchased from The Jackson 
Laboratory (Bar Harbor, ME).  Mice were housed in a pathogen-free barrier 
facility accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care.  All procedures were approved by the University of 
Louisville Institutional Animal Care and Use Committee.   
Food and tap water were allowed ad libitum throughout the experiment, 
except for a single 6 hour fast before glucose tolerance testing (see sections 
below for more details).  One week prior to the initiation of OLZ, animals were 
switched from laboratory chow to standardized diets (Harlan Laboratories, 
Madison, WI) to avoid any batch-to-batch variability in the food content.76  In 
studies designed to test the effects of OLZ alone, pellets of TD.08485 (Low-Fat 
Control Diet; 13% calories from fat) were supplied fresh twice per week.  In 
studies designed to test the interaction between OLZ and high-fat diet, pellets of 
either TD.08485 or TD.88137 (Adjusted Calories Diet; 42% calories from fat) 




subtracting the weight of the pellets remaining at the end of each semi-weekly 
feeding period. 
B.  Chronic model of olanzapine exposure 
Olanzapine (8 mg/kg/d) or vehicle (saline) was given s.c. for 28 days via 
surgically implanted osmotic minipumps (Alzet, Cupertino, CA).  This dose of 
OLZ was previously determined by positron emission tomography scan to 
achieve a therapeutically-relevant level of dopamine (D2) receptor occupancy in 
mice.77  The s.c. route of administration was chosen to maintain a steady dosage 
of OLZ, and because parenteral and oral formulations of OLZ have already 
demonstrated comparable efficacy in vivo.78  To avoid concerns of OLZ 
degradation, pumps were replaced after two weeks.79  Individual mouse weights 
were recorded on a weekly basis.  After 28 days, the mice were anesthetized 
with ketamine/xylazine (100/15 mg/kg i.p.) and minipumps were removed and 
weighed.  Body composition was assessed by dual-energy x-ray absorptiometry 
(DEXA Scan)80 using a Lunar PIXImus densitometer (Lunar Corp., Madison, WI).  
Blood was collected from the vena cava just prior to sacrifice by exsanguination, 
and citrated plasma was stored at −80 °C for later analysis.  Portions of liver 
tissue were frozen immediately in liquid nitrogen, fixed in 10% neutral buffered 
formalin, or frozen-fixed in cold embedding medium (Tissue-Tek OCT compound, 
Sakura Finetek, Torrance, CA) for subsequent sectioning and mounting on 





C. Oral glucose tolerance test (OGTT)   
Glucose tolerance was evaluated at day 25 of OLZ exposure using an 
OGTT method optimized by Andrikopoulos et al.81  Mice were transferred to 
cages that had been cleared of food and bedding and fasted for 6 hrs.  Blood 
was sampled from the tail vein immediately after fasting, and then 15, 30, 60, 90 
and 120 min. after oral administration of 2mg/kg D-(+)-glucose (Sigma, St. Louis, 
MO) solution.  Glucose concentrations were measured using an Accu-Chek® 
Aviva Plus glucometer and test strips (Roche Diagnostics Corp., Indianapolis, 
IN).  
D. Biochemical analyses 
Plasma levels of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total cholesterol, HDL, LDL, VLDL, triglycerides (TG), 
and glucose were determined by the Piccolo® Lipid Panel Plus Reagent Disc, 
used with the Piccolo xpress™ Chemistry Analyzer (Abaxis, Inc., Union City, 
CA), according to the manufacturer’s instructions.     
E.  Hepatic lipid measurement 
Hepatic lipids (TG and NEFA – non-esterified fatty acids) were extracted 
as described by Bligh and Dyer.82  Briefly, mouse livers were pulverized in a 
mortar filled with liquid nitrogen.  Lipids were extracted from the pulverized tissue 
by separation in a 1:2 solution of methanol and chloroform, then dried under 




(Sigma, St Louis, MO).  Results were normalized to wet weight of extracted 
tissue.   
F. Histology 
 General morphology   1.
Hematoxylin and eosin (H&E) staining was used to assess overall hepatic 
structure.  Paraffin-embedded sections of liver (5 μm) were deparaffinized and 
rehydrated, stained with hematoxylin for 45 seconds, washed, and 
counterstained with eosin for 3 minutes.  Stained sections were then mounted 
with Permount (Fisher Scientific, Fair Lawn, NJ) and glass coverslips. 
 Neutral lipids 2.
For detection of neutral lipids in tissue, 10 µm sections of frozen-fixed liver 
embedded in OCT Compound were cut and stained with Oil Red O (Sigma 
Chemical Co., St. Louis, MO) for 10 min., washed, and counterstained with 
hematoxylin for 45 seconds before mounting with Crystal Mount™ (Sigma, St. 
Louis, MO).  The extent of oil Red O staining was defined as the percent of the 
field area within the default color range determined by image analysis software.83 
 Glycogen and glycoprotein storage    3.
Carbohydrate storage was visualized with Periodic acid-Schiff (PAS) 
reagent staining.  Paraffin sections were oxidized in 0.5% periodic acid solution 
for 5 min., washed, placed in Schiff reagent (Sigma) for 15 min., washed, and 




extent of PAS staining was defined as the percent of the microscope field area 
within the default color range determined by image analysis software.83 
 Lipid peroxidation   4.
Adducts of 4-hydroxynonenal, an α,β-unsaturated hydroxyalkenal 
produced by lipid peroxidation, were detected with a modified version of 
immunohistochemical techniques described by Arteel et al.83,84  Specifically, 
tissue sections were stained using a rabbit polyclonal 4-HNE antibody (Alpha 
Diagnostic, San Antonio, Texas) and a kit based on a routine biotin-streptavidin-
peroxidase staining technique (VECTASTAIN ABC kit, Vector Laboratories, 
Burlingame, CA).  Once the antibody-biotin-peroxidase complex was formed, 
diaminobenzidine (ImmPACT™ DAB peroxidase substrate, Vector Laboratories) 
was added as the peroxidase substrate.  After the immunostaining procedure, 
tissue sections were counterstained with hematoxylin and mounted.  Staining 
was quantitated as the percentage of brown labeling (i.e., DAB) of the field area 
minus the area of the acellular spaces.  
 Neutrophil accumulation   5.
For measurement of hepatic neutrophil infiltration, the naphthol AS-D 
chloroacetate esterase (CAE) kit (Sigma, St. Louis, MO) was used according to 
the manufacturer’s instructions.  CAE-positive cells were quantitated by counting 
(positive cells per 1000 hepatocytes) in randomly selected fields.85 
 Apoptosis   6.




labeling (TUNEL) employing a commercially available kit (ApopTag® Red In Situ 
Apoptosis Detection Kit, CHEMICON International, Temecula, CA).  Slides were 
mounted with VECTASHIELD mounting medium containing DAPI (Vector 
Laboratories) and glass coverslips.  Apoptotic cells were counted in the same 
manner as CAE-positive cells (see Neutrophil accumulation above). 
A MetaMorph™ image analysis system (Universal Imaging Corporation, 
Downingtown, PA) equipped with a Nikon microscope (Nikon, Melville, NY) was 
used to capture and analyze the results of the staining procedures described 
above.  Positive staining was not detected when tissues were processed without 
primary antibody, indicating that nonspecific binding of secondary antibody did 
not occur under these conditions. 
G. RNA Isolation and Real-Time RT-PCR 
Message levels of selected genes were detected by real-time reverse-
transcriptase PCR. Total RNA was extracted from tissue samples by a guanidium 
thiocyanate-based method (Tel-Test, Austin, TX).  RNA concentrations were 
determined spectrophotometrically, and 1 μg total RNA was reverse transcribed 
using an MMLV reverse transcriptase kit (Quanta Biosciences, Gaithersburg, 
MD).  The cDNA was added to a mixture containing premade primers and probes 
(Applied Biosystems, Foster City, CA) and a ready-to-use reaction buffer (Quanta 
Biosciences).  Amplification reactions were performed using ABI StepOne Plus 
Software (Applied Biosystems).  The comparative CT method was used to 




determines the amount of target, normalized to an endogenous reference (β-
actin) and relative to a calibrator (2-∆∆Ct). 
H. Glycogen Determination 
To determine hepatic glycogen content, mouse livers (50-100 mg) were 
weighed and placed immediately in 30% KOH (500 μl), digested at 100°C for 20 
min, then cooled to room temperature.  To the cooled digest, 95% EtOH (625 μl) 
was added and allowed to stand overnight at room temperature.  The samples 
were then centrifuged at 16000 × g (4°C) for 15 min.  The resultant pellet was 
resuspended in 1ml water.  Hepatic glycogen content was then determined with 
anthrone reagent as described by Seifter et al.86 and modified for a 96-well plate 
by Leyva et al.87   Glycogen content was calculated from glucose stand curve 
and reported at μg/g tissue. 
I. Immunoblots 
Frozen liver samples were homogenized (Polytron Kinematica, Lucerne, 
Switzerland) in RIPA buffer (20 mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 1 
mM EGTA,  1 mM β-glycerophosphate, 1 mM Na3VO4, and 1% w/w Triton X-
100) containing protease, tyrosine phosphatase, and serine/threonine 
phosphatase inhibitor cocktails (Sigma, St. Louis, MO).  Lysates were agitated 
with an ultrasonic probe and subsequently centrifuged for 5 min. at 16,000 × g.  
Protein concentration of the supernatants was determined with the Bio-Rad DC 
Protein Assay (Bio-Rad, Hercules, CA, USA); 100 μg of total protein were mixed 
with 4× sample loading buffer (250 mM Tris pH 7.4, 10% SDS, 20% 2-




at 95°C for 5 min.  Samples were loaded onto SDS–polyacrylamide gels (Bio-
Rad Laboratories, Hercules, CA), followed by electrophoresis and Western 
blotting onto PVDF membranes (Hybond P, Amersham Biosciences, Piscataway, 
NJ, USA).  Antibodies against p-AMPKα, AMPKα, p-Akt, Akt, p-mTOR, mTOR, p-
p70S6K, p-4EBP1 (Cell Signaling, Danvers, MA, USA) and p70S6K and 4EBP1 
(Bethyl Laboratories, Montgomery, TX) were used at the dilutions recommended 
by the suppliers.  Horseradish peroxidase-coupled secondary antibodies and 
chemiluminescence detection reagents were from Pierce (Rockford, IL, USA).  
The signals were detected employing Classic Blue™ autoradiography film BX 
(MIDSCI, St. Louis, MO).  Densitometric quantitation was performed with UN-
SCAN IT analysis software (Silk Scientific, Orem, UT).  
J. In vitro measurement of oxygen consumption and proton production 
rates (OCR and PPR) 
Bioenergetic measurements were made using an XF96 Extracellular Flux 
Analyzer (Seahorse Biosciences, Billerica, MA).  HepG2 cells (American Type 
Culture Collection, Manassas, VA) were plated at 10,000 cells per well and 
grown for 24 hrs. in DMEM (Gibco, Carlsbad, CA) containing either glucose (25 
mM) or galactose (10 mM) and 6 mM pyruvate.  (Immortalized cells preferentially 
use glycolysis to meet energy demands, even in the presence of adequate 
oxygen.88  Anaerobic glycolysis of galactose yields no net ATP, however, forcing 
cells to rely on oxidative phosphorylation for survival.)  Cells were then treated 
with graded concentrations of olanzapine from 0–25 μM.  One hour prior to the 




(Seahorse Biosciences) containing the same concentrations of sugars, pyruvate 
or olanzapine.  The XF96 Extracellular Flux analyzer measures OCR (oxygen 
consumption rate) and PPR (proton production rate) by creating a small transient 
chamber in specialized plates.  Seeding density was optimized under the cell 
culture conditions described to ensure linear oxygen consumption and adequate 
re-equilibration during the re-equilibration phases.  Coupled and uncoupled OCR 
and PPR measurements were made by addition of oligomycin (1 μg/ml) and 
FCCP (1 μM), respectively, through sequential injections from ports in the 
Seahorse Flux Pak cartridges.    
K. GC×GC-TOF MS and Pathway Analysis 
 Metabolite sample preparation 1.
A sample of liver tissue was weighed and homogenized for 2 min after 
adding water at a ratio of 100 mg liver tissue/mL water. The homogenized 
sample was then stored at –80 °C until use. A 100 µL aliquot of the homogenized 
liver sample and 400 µL ice cold methanol were mixed and vortexed for 2 min, 
then incubated for 10 min on ice followed by another 2 min vortex. The mixtures 
were centrifuged at 4 °C for 10 min at 15000 rpm. 400 µL of the supernatant was 
aspirated into a micro centrifuge tube and dried by SpeedVac overnight. The 
extracted metabolites were then dissolved in 40 µL acetonitrile. After adding 40 
µL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) mixed with 
1% tert-butyldimethylchlorosilane (TBDMSCI), the mixture was sonicated for 3 




were then transferred to GC vials for analysis. The derivatization was performed 
just before GC×GC–TOF MS analysis. 
 GC×GC –TOF MS analysis 2.
The LECO Pegasus 4D GC×GC –TOF MS instrument was equipped with 
an Agilent 6890 gas chromatograph and a Gerstel MPS2 auto-sampler 
(GERSTEL Inc., Linthicum, MD), featuring a LECO two-stage cryogenic 
modulator and secondary oven. The primary column was a 60 m × 0.25 mm 1dc 
× 0.25 μm 1df, DB-5ms GC capillary column (phenyl arylene polymer virtually 
equivalent to a (5%-phenyl)-methylpolysiloxane). A second GC column of 1 m × 
0.25 mm 1dc × 0.25 μm 2df, DB17ms ((50%-phenyl)-methylpolysiloxane) was 
placed inside the secondary GC oven after the thermal modulator. Both columns 
were obtained from Agilent Technologies (Agilent Technologies J&W, Santa 
Clara, CA). The helium carrier gas (99.999% purity) flow rate was set to 2.0 
mL/min at a corrected constant flow via pressure ramps. The inlet temperature 
was set at 280 °C. The primary column temperature was programmed with an 
initial temperature of 60 °C for 0.5 min and then ramped at 5 °C/min to 270 °C 
and kept for 15 min. The secondary column temperature program was set to an 
initial temperature of 70 °C for 0.5 min and then also ramped at the same 
temperature gradient employed in the first column to 280 °C accordingly. The 
thermal modulator was set to +15 °C relative to the primary oven, and a 
modulation time of PM = 2 s was used. The mass range was set as 29−800 m/z 
with an acquisition rate of 200 mass spectra per second. The ion source 




the detector voltage was 1450 V with electron energy of 70 eV. The acceleration 
voltage was turned on after a solvent delay of 674 s. The split ratio was set at 
25:1. 
 GC×GC–TOF MS data analysis 3.
The GC×GC–TOF MS data were processed using LECO’s instrument 
control software ChromaTOF for peak picking and tentative metabolite 
identification, followed by retention index matching, peak merging, peak list 
alignment, normalization, and statistical significance test using MetPP software.89 
For metabolite identification using ChromaTOF, each chromatographic peak was 
tentatively assigned to a metabolite if its experimental mass spectrum and a 
database spectrum have a spectral similarity score no less than 600. The 
retention index matching in MetPP was performed using the iMatch method with 
the p-value threshold set as p ≤ 0.001.90 The pairwise two-tail t-test was used to 
determine whether a metabolite has a significance abundance difference 
between sample groups by setting the threshold of false discovery rate q ≤ 0.3. 
L. Sulforaphane administration 
Sulforaphane (SFN), a known Nrf2 inducer, was investigated as a possible 
preventative measure against weight gain and oxidative injury.  In the 
experiments discussed in Chapter V, mice received SFN diluted in water (90 
mg/kg/d p.o.; LKT Laboratories, St. Paul, MN) alongside chronic OLZ treatment 
and HFD feeding.  SFN treatment began one week prior to OLZ administration 




until the day of sacrifice.  Mice not receiving sulforaphane received equivalent 










The atypical antipsychotic olanzapine is a first-line treatment for psychosis 
and mood disorders.  The major side effects of this centrally-acting drug occur in 
the peripheral tissues: weight gain, hepatic steatosis, and glucose intolerance.  
The exact mechanism or mechanisms leading to side effect development with 
OLZ are unknown.  The purpose of the following experiments was to reveal the 
biochemical pathways involved in OLZ metabolism and toxicity, primarily in liver.  
B. Experimental procedures 
 Animals and treatments 1.
All mice in this experiment were fed purified TD.08485 diet starting one 
week prior to administration of OLZ or vehicle. OLZ administration and sacrifice 
procedures are described in Chapter II. See also: Timeline, Figure 3.1, panel A. 
 Oral glucose tolerance test 2.




 Biochemical analyses and histology 3.
ALT, AST, cholesterol, TG and glucose were determined in plasma after 
four weeks of OLZ administration according to the methods detailed in Chapter II. 
Liver sections were stained with H&E, Oil Red O, and Periodic acid-Schiff 
reagent as described in Chapter II. 
 RNA isolation and real-time RT-PCR 4.
See detailed methods in Chapter II. 
 Immunoblots 5.
Immunoblotting was used to assess the phosphorylation status of mTOR, 
AMPK, 4EBP1, p70S6K and Akt, as described in Chapter II. 
 In vitro metabolic measurements 6.
HepG2 cells were exposed to varying concentrations of OLZ and 
measured with an extracellular flux analyzer as described in Chapter II. 
 Metabolomic analyses 7.
GC×GC-TOF MS was performed and the results were analyzed as 
previously described in Chapter II. 
C. Results 
 OLZ administration increases weight and adiposity 1.
All animals gained weight during the course of the study and there was no 
mortality in any group.  OLZ administration did not significantly increase food 




food consumption measurements for each group were nearly identical, OLZ 
administration significantly increased body weight by ~40% over controls (Figure 
3.2, panel A), similar to what has been observed previously by other groups.91  
An increase in body fat percentage and gonadal fat pad mass accompanied the 
weight gain (Figure 3.2, panel B) in OLZ-exposed animals. 
 OLZ promotes hepatic lipid accumulation 2.
Obesity and/or metabolic syndrome commonly cause lipids to accumulate 
in the liver (i.e., steatosis).61  As OLZ administration increased body weight and 
total body fat (Figure 3.2), the effect of OLZ on hepatic lipid accumulation was 
determined.  A crude index of hepatic lipid accumulation is liver size.  OLZ 
increased liver weight as indicated by the elevation in liver weight to body weight 
ratio (Figure 3.3, panel C).  Four weeks of OLZ treatment also increased hepatic 
fat, as indicated by the presence of macro- and micro-vesicular lipid droplets in 
hematoxylin and eosin-stained tissue (Figure 3.3, panel A, top).  This effect of 
OLZ on hepatic lipid accumulation was confirmed by Oil Red O staining (panel A, 
bottom).  OLZ administration significantly elevated hepatic triglyceride (TG) 
content ~2-fold (Figure 3.3, panel B); interestingly, this increase in TG was not 
coupled with a concomitant increase in hepatic non-esterified fatty acids (NEFA).  
This increase in hepatic lipids was paralleled by a significant increase in plasma 
triglycerides and VLDL (Table 3.1).  These effects of OLZ were also 
accompanied by liver injury, as indicated by significant elevations of plasma ALT 
(~2-fold) and AST (~1.5 fold; Table 3.1). 




Hepatic steatosis is often mediated via direct alterations in the expression 
of genes key to lipid and carbohydrate metabolism.  To explore the effects of 
OLZ on hepatic energy metabolism, mRNA expression of genes that are key in 
regulating the synthesis and catabolism of carbohydrates and lipids was 
examined by qRT-PCR (Figure 3.4).  Four weeks of OLZ administration 
significantly downregulated the expression of a number of genes involved in lipid 
biosynthesis, including sterol regulatory element-binding protein 1 (Srebf1), fatty 
acid synthase (Fasn), and ATP citrate lyase (Acly).  Similarly, OLZ treatment 
upregulated expression of glycogen synthase kinase-3β (Gsk3b), a protein that 
suppresses glycogen synthesis.  These changes in expression of anabolism-
regulating genes were accompanied by a significant (2.5-fold) increase in 
expression of glucokinase (Gck), a rate-limiting enzyme in glycolysis.  Expression 
of carnitine palmitoyltransferase 1a (Cpt1a), which encodes the rate-limiting 
enzyme in fatty acid β-oxidation, was unchanged, as were phosphoenolpyruvate 
carboxykinase 1 (Pck1; gluconeogenesis) and glucose transporter type 1 and 
glucose transporter type 4 (Glut1 and Glut4; basal and insulin-mediated glucose 
transport, respectively). 
 Effects of OLZ on mitochondrial respiration 4.
The mRNA expression data suggest that OLZ administration favors 
glycolysis (Figure 3.4).  Previous studies with isolated brain mitochondria have 
suggested that OLZ partially inhibits mitochondrial respiration (e.g.,92).  The effect 
of OLZ exposure on the balance between glycolysis and mitochondrial 




glucose- and galactose-containing media (see Experimental Procedures in 
Chapter II and diagram in Figure 3.5).  Under these conditions, proton production 
rate (PPR) is used as an index of glycolysis, and the oxygen consumption rate 
(OCR) is used as an index of mitochondrial function (Figure. 3.7).  As expected, 
inhibition of mitochondrial respiration with oligomycin, which forced the cells to 
rely on anaerobic glycolysis, decreased the rate of OCR, while simultaneously 
increasing the rate of PPR, thereby greatly increasing the PPR:OCR ratio.  
Uncoupling the mitochondria with FCCP increased the OCR while still 
maintaining an elevated PPR, causing the PPR:OCR ratio to decrease relative to 
oligomycin, but still remain elevated relative to basal (Figure 3.7, panels A, B, C, 
D, E, and F).  In glucose-containing media, OLZ had no apparent effect on OCR 
or PPR at any concentration. When the Warburg/Crabtree effect was overcome 
by incubating HepG2 cells in galactose-containing media,88 the ratio of PPR:OCR 
was dramatically decreased, as the cells were forced to rely on oxidative 
phosphorylation.93  Under these conditions, OLZ incubation caused a dose-
dependent increase in PPR, without significantly affecting OCR (panels G and 
H).   
 Effects of OLZ on glucose and glycogen expenditure  5.
OLZ increased basal (unfasted) plasma glucose, as indicated by plasma 
taken at sacrifice (Table 3.1).  Previous studies have indicated that OLZ 
administration may cause insulin resistance and/or glucose intolerance.94  OLZ 
also antagonizes serotonin, which is a positive mediator of glycogen synthesis.95  




tolerance, fasted mice were subjected to the OGTT at 25 days of vehicle or drug 
administration (see Experimental Procedures in Chapter II and Figure 3.7, panel 
A in this chapter).  OLZ exposure significantly increased plasma glucose 
concentrations 15 minutes after bolus gavage (panel A), but values were similar 
to controls at all subsequent time points.  As mentioned above, the expression of 
a key inhibitor of glycogen storage (Gsk3b) was significantly increased in livers of 
OLZ-exposed mice (see Figure 3.4).  The effect of OLZ administration on hepatic 
glycogen storage was therefore assessed by Periodic acid-Schiff reagent (PAS) 
staining.  OLZ administration decreased the amount of glycogen stored in 
unfasted liver by 2-fold compared to controls (Figure 3.7, panel B, representative 
photomicrographs, and panel C, quantitative image analysis).   
 OLZ effects on the hepatic metabolome 6.
Examining metabolites on an individual basis is time-consuming, and the 
smaller amounts of data produced may unnecessarily narrow the scope of a 
study.  Metabolomic analysis was therefore used to simultaneously characterize 
several effects of OLZ on the liver (Figure 3.8).  Metabolites that varied 
significantly between the OLZ group and the control group were then analyzed 
with pathway analysis software, which predicted and mapped the pathways that 
may be relevant to OLZ treatment (Figure 3.9).  Among other findings, levels of 
amino acids were significantly affected by OLZ: L-glutamine, a putative mediator 
of insulin secretion96 and mTOR activation,97 was increased in animals 
administered OLZ.  Network analysis further predicted the involvement of amino 




shown to function as regulators of mTOR signaling,97-99 and EAAT3, which 
conversely is regulated by mTOR.100 
 OLZ mediates signaling through mTOR and related pathways  7.
OLZ administration has been shown to increase peripheral levels of 
glutamate,101,102 which can increase the flux of branched chain amino acids 
(BCAAs) and/or branched chain α -ketoacids in tissue.103,104  BCAAs,105 their α-
ketoacid analogs,106 and glutamine107 have all been identified as potential 
activators of mammalian target of rapamycin (mTOR) and/or mTOR-dependent 
signaling cascades.  Atypical antipsychotics have also been shown to increase 
glutamine in the brains of postmortem schizophrenia patients.108  Given the key 
role of mTOR in bioenergetic regulation109 and the effects of OLZ on glutamine, 
(Figure 3.8), mTOR and related proteins were examined by Western blot (Figure 
3.10).  OLZ administration increased mTOR activation, as indicated by a 
significant increase in phosphorylation at Ser2448.110  OLZ administration also 
increased phosphorylation of p70S6K at Thr389 and 4EBP1 at Thr37/46, 
indicating mTORC1 activation,111 as well as Akt phosphorylation at Ser473, 
indicating mTORC2 activation.112  Strangely, OLZ treatment concomitantly 
increased AMPK activation (Figure 3.10), as indicated by an increase in 
phosphorylation at Thr172.113 
D. Discussion 
The serotonin-dopamine antagonist OLZ is a valuable addition to the 
psychiatric pharmacopeia, but it also presents new challenges for doctors and 




older antipsychotics, OLZ causes a number of adverse effects that restrict its 
use, such as obesity and elevated cholesterol.  In order for patients to benefit 
from OLZ without suffering additional metabolic complications, preventive agents 
and/or treatments must be aimed at the root causes of dysmetabolism during 
OLZ treatment.  Thus far the origins of OLZ dysmetabolism have been elusive, 
as even the mechanisms that mediate OLZ’s desirable therapeutic effects are 
poorly understood. 
The findings from this study – namely, that OLZ activates both AMPK and 
mTOR, and that this activation may result from altered amino acid transport (see 
diagram, Figure 3.11) – are therefore important steps toward improving the 
safety and tolerability of antipsychotic treatment.  An earlier intervention 
proposed for the metabolic side effects of OLZ was metformin, a biguanide drug 
often prescribed for type II diabetes.  Clinical trials of metformin as an adjunct to 
OLZ therapy have shown disappointingly little improvement in metabolic 
symptoms, however.115  This lack of effect may be due to the fact that AMPK 
activation is a major mechanism of action for metformin, and AMPK is already 
activated by OLZ administration. 
Targeting mTOR may instead work better than targeting AMPK.  It has 
been suggested that “normalizing” mTOR overactivation could be beneficial for 
managing obesity and diabetes.116  While OLZ-mediated dysmetabolism differs 
slightly from most cases of metabolic syndrome – a point which is clearly 
illustrated by the differential activation of AMPK – the effects on mTOR appear 




as tacrolimus, given at a sub-immunosuppressive dose, may be applicable in 
both primary and OLZ-mediated metabolic dysfunction.   
Future studies will be needed to confirm the therapeutic significance of 
mTOR suppression as an adjunct to antipsychotic therapy.  In certain 
experimental models, mTOR inhibitors like rapamycin have exacerbated glucose 
intolerance117 and dyslipidemia;118 in other studies, mTOR inhibitors have 
improved metabolic homeostasis.119-121  Appropriate dosing appears crucial to 
the ultimate outcome of treatment with mTOR inhibitors.122  It should also be 
determined what effects, if any, mTOR inhibitors have on mental functioning and 
overall OLZ efficacy.  The glutamatergic model of mental illness proposes that 
antipsychotic disorders are disorders of excitatory amino acid metabolism.123  






Table 3.1: Plasma parameters after 4 weeks of OLZ treatment 
 
  Control OLZ 






42 ± 2 
 










50 ± 6 
 
34 ± 4 
 
62 ± 3 
 


















8 ± 2 
 
9 ± 1 
 
33 ± 9 
 
56 ± 2 
 
4 ± 2 
 
16 ± 1* 
 
76 ± 9* 
 
80 ± 6* 
 
Animals and treatments are described in Experimental Procedures.  Data 
are means ±S.E.M. (n=4-8) and are reported as indicated in the individual rows. 





Figure 3.1: Experimental timeline 
 
Mice were switched to purified TD.08485 diet one week prior to OLZ 
administration (8 mg/kg/d, s.c.).  Oral glucose tolerance testing (OGTT) was 
performed after 25 days of OLZ administration.  After four weeks of continuous 
















Figure 3.2: Effect of OLZ on body weight gain and adiposity 
 
Mice were treated with OLZ for four weeks as described in Chapter II.  
Average weekly food consumption and weight gain are shown (panel A).  Body 
fat as a percentage of total body weight was measured by x-ray absorptiometry 
and gonadal fat pads were removed and weighed at sacrifice (panel B).  Data are 









































































Figure 3.3: OLZ promotes hepatic lipid accumulation 
 
General histology is represented by hematoxylin and eosin staining (panel 
A, top).  Neutral lipid accumulation is shown with Oil Red O staining (panel A, 
bottom).  Hepatic triglyceride (TG) and non-esterified fatty acid (NEFA) contents 
(panel B) were determined after chloroform:methanol extraction as described in 
Experimental Procedures.  Liver weight measurements taken at sacrifice are 
expressed as a percentage of total body weight, also measured at sacrifice 








Figure 3.4: Effects of OLZ on hepatic gene expression 
 
Hepatic mRNA expression of genes for lipid metabolism (top) and 
carbohydrate metabolism (bottom) was determined by qRT-PCR after four weeks 
of continuous OLZ treatment, as described in Experimental Procedures.  Data 













































Figure 3.5: Glucose vs. galactose media for immortalized cells 
 
Panel A: In primary cells (“normal” cells), energy requirements are mostly 
met by producing ATP via oxidative phosphorylation (OXPHOS), with glycolysis 
making a small contribution to overall energy status. Immortalized cells, in 
contrast, primarily generate ATP through glycolysis.  Panel B: Because 
metabolism of galactose produces no net ATP, immortalized cells must rely on 









Figure 3.6: In vitro metabolism of OLZ-treated HepG2 cells 
Respiration was measured in HepG2 cells grown in either glucose or 
galactose and graded concentrations of OLZ (0 – 25 μM).  PPR (panels A and 
B), OCR (panels C and D), and PPR:OCR (panels E and F) are shown as a 
function of time for 0 and 25 μM OLZ, with both glucose and galactose media. 
Measurements of PPR and OCR are also shown for galactose-grown cells in 
panels G and H  Basal = 10 minutes before the addition of oligomycin; Oligo = 10 
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Figure 3.7: Effects of OLZ on glucose and glycogen expenditure 
 
Glucose tolerance (panel A) was assessed as described in Experimental 
Procedures.  Liver sections were stained with Periodic acid-Schiff reagent and 
representative photomicrographs are depicted (panel B).  PAS staining was 
quantitated (panel C) as described in Chapter II.  Data are means ±S.E.M.(n=4-







Figure 3.8: OLZ effects on the hepatic metabolome 
 
Liver samples were derivatized as described in Chapter II and metabolites 
determined by GC×GC-TOF MS.  Relative abundance data is shown for selected 
small molecule metabolites.  Data are means ±S.E.M.(n=4-8).  *, P < .05 
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Figure 3.9: Metabolic pathways 
 
Metabolites identified by GC×GC-TOF MS were evaluated with 
MetaCore™ software and used to construct a pathway map.  Targets related to 










Figure 3.10: OLZ mediates signaling through mTOR and related pathways 
 
Liver homogenates were prepared as described in Experimental 
Procedures, Chapter II.  Representative immunoblots are shown (panel A).  
Quantitative analysis was performed and the ratio of phosphorylated to total 










Figure 3.11: Hypothesized mechanism of OLZ-induced metabolic 
dysregulation in liver 
 
OLZ promotes flux of glutamine (Gln) and leucine (Leu) through solute 
carrier 38a2 (SLC38A2 or SNAT2) and solute carrier 7a5 (SLC7A5 or LAT1). 
Increased concentrations of Gln and Leu induce mTOR signaling.  Excess 
intracellular Leu acts as a nitrogen donor in the branched chain aminotransferase 
(BCAT) reaction that forms glutamate (Glu).  Leu and Glu also contribute 
metabolic intermediates (e.g., acetyl CoA) to the Krebs cycle.  Interestingly, 
AMPK was simultaneously activated under these conditions (see discussion in 





































HIGH-FAT DIET EXACERBATES OLANZAPINE-INDUCED LIVER INJURY 
 
A. Introduction 
In the preceding sections of this dissertation it was noted that weight gain 
and obesity caused by OLZ are serious health risks as well as barriers to 
successful treatment of mental illness.  OLZ administration causes weight gain in 
normal-weight individuals; OLZ use may then be especially detrimental for 
overweight patients or patients who consume high-fat, high-calorie diets.  Indeed, 
OLZ has been shown to “unmask” metabolic syndrome and type II diabetes in 
previously asymptomatic individuals.32,124,125  The purpose of these experiments, 
therefore, was to determine the interactions that result from concurrent OLZ 
administration and HFD feeding, and to isolate the unique pathological features 
of these interactions. 
B. Experimental Procedures 
 Animals and treatments 1.
Mice were separated into four groups (2x2 factorial design), receiving 
either TD.08485 low-fat or TD.88137 high-fat diet and either OLZ or vehicle 




period.  Drug administration and sacrifice procedure are described in greater 
detail in the Experimental Procedures chapter (Chapter II). 
 Oral glucose tolerance test (OGTT) 2.
Glucose tolerance testing was performed as described in Chapter II. 
 Glycogen determinations 3.
Glycogen was measured in liver tissue aliquots as described in Chapter II. 
 RNA isolation and real-time RT-PCR 4.
Details for RNA isolation and PCR procedure are found in Chapter II. 
 Biochemical analyses and histology 5.
Liver sections were stained with H&E, Oil Red O, CAE, PAS, TUNEL and 
4- HNE as described in Chapter II. 
 Lipid determinations 6.
Hepatic lipids were measured as previously discussed in Chapter II. 
C. Results 
 High-fat diet (HFD) increases food consumption and exacerbates 1.
weight gain caused by OLZ 
All animals gained weight over the course of the study and no mortality 
was observed in any group.  Mice fed HFD consumed more food and gained 
more weight on average than mice fed LFD (Figure 4.2, panels A and B).  OLZ 
did not have any effect on food consumption, but added to body weight gain in 




mass, which was further increased by concurrent HFD feeding (panel C).  OLZ 
and HFD promoted overall body fat accumulation as shown by DEXA scan 
(representative images, panel D). 
 HFD aggravates OLZ-induced liver injury 2.
Previous studies have shown that feeding mice a diet enriched in 
triglycerides and cholesterol (i.e., the “Western diet”) damages the liver and may 
contribute to the onset of NAFLD.  Studies from this laboratory have also linked 
OLZ administration to early indices of liver damage.  Liver injury was indeed 
observed in OLZ-treated animals, and this liver injury was aggravated by 
concurrent HFD feeding.  As in previous work, four weeks of OLZ increased fat 
accumulation across all regions of the liver, as shown by H&E staining (Figure 
4.3, panel A, top row).  Co-administration of HFD further increased the fat 
accumulation resulting from OLZ alone.  Neutrophil infiltration in liver was 
increased by HFD or OLZ alone, and more so by HFD and OLZ together 
(representative pictures in bottom row of panel A and cell counting, panel D).  
OLZ administration elevated circulating hepatic transaminases, a common 
indicator of hepatocyte death (panels B and C).  HFD alone had no effect on 
transaminase levels; however, in conjunction with OLZ, HFD raised ALT and 
AST to levels greater than OLZ alone.  OLZ and HFD separately increased the 
liver weight to body weight ratio, but the combination of OLZ and HFD produced 
no additional change (panel E). 




Hematoxylin and eosin staining had demonstrated steatosis with OLZ and 
HFD both alone and in combination.  Therefore, frozen liver sections were 
stained with Oil Red O (Figure 4.4, panel A) and staining intensity (i.e., extent of 
lipid accumulation) was quantitated (panel B).  Minimal staining intensity was 
seen with LFD feeding, indicating very little hepatic fat accumulation.  OLZ 
administration caused a 1.5-fold increase in micro- and macrovesicular steatosis, 
as determined by image analysis.  HFD by itself caused a 2-fold increase in 
steatosis.  When OLZ and HFD were administered together, steatosis increased 
2.5-fold compared to LFD alone.  Hepatic lipid extraction elaborated upon these 
Oil Red O data: OLZ and HFD separately doubled triglyceride (TG) content in 
liver, and together increased TG fourfold (panel C).  Hepatic free fatty acids 
(NEFA) were elevated with HFD alone, but remained stable in all other treatment 
groups. 
 Effects of OLZ and HFD on glucose metabolism  4.
In vivo glucose metabolism was measured by oral glucose tolerance test 
(OGTT) after 25 days of drug administration and LFD or HFD consumption (see 
Experimental Procedures for additional details).  Four weeks of OLZ and/or HFD 
did not significantly alter plasma glucose concentrations after a 6 hour fast 
(Figure 4.5, panel A).  Following bolus glucose administration, however, plasma 
glucose was markedly elevated in both HFD- and OLZ-exposed animals.  
Exposure to OLZ and/or HFD also influenced glucose kinetics.  In mice given 
OLZ and HFD, either separately or in combination, peak plasma glucose was 




Interestingly, at the 30 minute time point, plasma glucose remained elevated in 
mice given HFD alone, but rapidly declined in mice given HFD and OLZ together.   
 HFD worsens OLZ-induced glycogen depletion 5.
A previous study by this group showed that OLZ exposure attenuated 
glycogen storage in liver.  Here, the interaction between OLZ and HFD was 
investigated.  Periodic acid-Schiff (PAS) staining showed that OLZ alone and 
HFD alone decreased hepatic glycogen reserves (Figure 4.5, panels B and C).  
Glycogen was additionally depleted by co-administration of OLZ and HFD.  
 Effects of HFD and OLZ on apoptosis and lipid peroxidation 6.
To better determine the cause of aggravated liver injury with concurrent 
HFD and OLZ, liver sections were stained for markers of apoptosis and lipid 
peroxidation.  Though few apoptotic cells were counted in any treatment group, 
HFD alone doubled the number of TUNEL-positive cells per 1,000 hepatocytes 
counted (Figure 4.6, panels A and B).  No additional change was seen with HFD 
and OLZ in combination.  Lipid peroxidation increased ~6-fold with OLZ alone, 
and ~8-fold with HFD and OLZ in combination (panel C).  
D. Discussion 
According to the “two hit” hypothesis, now widely accepted in the field of 
hepatology, liver disease development requires two or more compounding 
factors.  The first factor, or “hit,” increases sensitivity to injury by later insults.  For 
example, injecting mice with lipopolysaccharide (LPS) provokes an immune 




shortly afterward, liver injury becomes exponentially worse.126  The order of these 
two hits is probably not as important as the fact they occur in succession.  In an 
experiment by Yang et al. using obese (fa/fa) Zucker rats, LPS functioned as a 
second hit; the widespread hepatic steatosis already present in this genetic strain 
is considered to represent the first hit.48   
In the experiments reported in Chapter IV of this work, a different but 
complementary two-hit phenomenon was observed. OLZ produced toxic effects 
with both high- and low-fat diets, but the combined effects of OLZ and HFD 
noticeably exacerbated toxicity, increasing fat accumulation and inflammatory 
response, among other observable injuries.  Oxidative stress also markedly 
worsened during HFD + OLZ co-exposure.  These results parallel both Yang’s 
work and much subsequent research. The HFD + OLZ model, in demonstrating 
multiplied injury, maintains rather than innovates an important toxicological 
concept.   
The importance of the HFD + OLZ model instead arises from its 
implications for two overlapping clinical populations.  As mentioned in Chapter I, 
a majority of Americans today are overweight.  Of this overweight population, 
nearly half are obese (BMI ≥ 30).  Rates of overweight and obesity have 
increased over the last 50 years and show no evidence of decline.  While the 
prevalence of schizophrenia and affective disorders is much smaller (~1-
4%),127,128 the large and expanding proportions of the national weight problem 




Taken together, the results from this study illustrate the concept that more 
serious liver diseases may require multiple factors in their progression.  This 
demonstrates the need for additional monitoring of overweight or obese patients 
who also take olanzapine.  Also, because oxidative stress and inflammation were 
shown to worsen with HFD and OLZ, potential pharmacological interventions 
should be aimed at suppressing oxidative injury and/or exaggerated inflammatory 





Figure 4.1: Experimental timeline 
 
Mice were switched to purified low- or high-fat diets (LFD or HFD) one 
week prior to OLZ administration (8 mg/kg/d, s.c.).  Oral glucose tolerance testing 
(OGTT) was performed after 25 days of OLZ administration.  After four weeks of 
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Figure 4.2: High-fat diet (HFD) increases food consumption and 
exacerbates weight gain caused by OLZ 
 
Mice were fed HFD or LFD and administered OLZ or vehicle by osmotic 
minipumps for four weeks.  Food consumption and weight gain over the course 
of the four week study is shown in panels A and B.  Gonadal fat pads were 
removed at sacrifice and percentage of gonadal fat mass to total body mass was 
determined (panel C).  Body composition was measured by dual energy x-ray 
absorptiometry; representative scans are depicted (panel D).  Data are means 
±S.E.M.(n=4-8).  a, P<0.05 effect of HFD; b, P <0.05 effect of OLZ as determined 










Figure 4.3: HFD aggravates OLZ-induced liver injury 
 
Livers were stained with H&E to demonstrate general hepatocellular 
morphology (panel A, top). CAE staining was used to distinguish neutrophils from 
other cell types (panel A, bottom). Neutrophils were counted (panel D) as 
described in Chapter II.  Transaminase levels were measured in plasma taken at 
sacrifice (panels B and C). Liver weight is expressed as a percentage of total 
body weight (panel E).  Data are means ±S.E.M.(n=4-8).  a, P<0.05 effect of 
HFD; b, P <0.05 effect of OLZ as determined with two-way ANOVA and Holm-








Figure 4.4: OLZ and HFD promote hepatic lipid storage 
 
Frozen sections of liver were stained with Oil Red O as described in 
Materials and Methods (panel A, representative pictures) and staining was 
quantitated in all samples (panel B).  Lipids (TG and NEFA) were extracted from 
pulverized liver samples and determined by colorimetric assay (panel C).  Data 
are means ±S.E.M.(n=4-8).  a, P<0.05 effect of HFD; b, P <0.05 effect of OLZ as 








Figure 4.5: Effects of OLZ and HFD on glucose and glycogen metabolism 
 
OGTT was performed after 25 days of HFD or LFD feeding and exposure 
to OLZ or vehicle (panel A). Glycogen was isolated from snap-frozen liver 
samples and concentrations were determined by colorimetric assay (panel B). 
Liver samples fixed at sacrifice were stained with Periodic acid-Schiff reagent to 
identify glycogen (panel C).  Data are means ±S.E.M.(n=4-8).  a, P<0.05 effect of 
HFD; b, P <0.05 effect of OLZ as determined with two-way ANOVA and Holm-








Figure 4.6: Effects of OLZ on apoptosis and lipid peroxidation 
 
Frozen liver sections were stained using a modified TUNEL assay (panel 
A, top row).  Cells were counted (panel B) as described in the Histology section 
of Chapter II, Experimental Procedures.  Formalin-fixed liver sections were used 
for immunohistochemical detection of 4-HNE adducts (panel A, bottom row).  
Extent of staining (panel C) was quantitated as described in Experimental 
Procedures.  Data are means ±S.E.M.(n=4-8).  a, P<0.05 effect of HFD; b, P 
<0.05 effect of OLZ as determined with two-way ANOVA and Holm-Šidák 









PROTECTION FROM OLANZAPINE-INDUCED LIVER INJURY THROUGH 
ACTIVATION OF THE NRF2 PATHWAY 
 
A. Introduction 
Sulforaphane (SFN), an isothiocyanate phytochemical, is known to confer 
antioxidant protection in vivo.  Rather than directly reacting with oxidants, 
however, SFN works by inducing Nrf2, a transcription factor that binds to the 
promoter regions of several known antioxidant genes and enhances 
detoxification (diagram, Figure 5.1).  The route from SFN to Nrf2 is not entirely 
established.  In some studies, SFN’s isothiocyanate functional group is shown to 
participate as a Michael acceptor in the nucleophilic reaction with cysteine 
residues on Keap1.129  If Nrf2 remains bound to Keap1, it remains by definition in 
the cytosol, where it does not influence gene transcription and will eventually be 
targeted for degradation by the ubiquitin ligase Cul3.130  In addition to releasing 
Nrf2 from Keap1, SFN may raise overall expression of Nrf2.  Previous 
experiments from this laboratory have shown that SFN increases Nrf2 
abundance in both nuclear and cytoplasmic subcellular compartments, which 
may account for the enhanced antioxidant protection observed by others. 
 Both obesity and OLZ-induced dysmetabolism are mediated in part by 




intervention, e.g., SFN treatment.  It may then be possible to prevent hepatic 
injury from concurrent obesity and OLZ administration by pretreatment with SFN.  
The purpose of the current study was to test the protective effect of SFN against 
HFD- and OLZ-induced hepatic injury.  
B. Experimental procedures 
 Animals and treatments 1.
Mice were administered HFD and OLZ for four weeks.  Some mice were 
also administered SFN as described in Chapter II. 
 Biochemical analyses and histology 2.
ALT and AST were measured as previously described.  H&E, TUNEL, and 
4-HNE staining were performed as described in Chapter II. 
 Glycogen determinations 3.
Glycogen was determined in aliquots of frozen liver as described in 
Chapter II. 
 Lipid determinations 4.
Lipids were extracted and analyzed as discussed in Chapter II. 
C. Results  
 SFN prevents steatosis and liver injury caused by co-administration 1.
of HFD and OLZ 
Histological changes were assessed by H&E staining (Figure 5.2, panel 




SFN treatment decreased fat accumulation in liver (panel A) in addition to 
decreasing neutrophil infiltration/inflammation (panel A, inset).  ALT and AST, 
commonly used as markers of liver injury, decreased in parallel with the changes 
in histology (panel B). 
 SFN improves lipid and carbohydrate metabolism in mice 2.
administered HFD and OLZ 
SFN blunted the characteristic triglyceride (TG) accumulation caused by 
HFD and OLZ (Figure 5.2, panel B).  SFN also rescued non-esterified fatty acid 
(NEFA) levels which are paradoxically low during OLZ administration,70,104 and 
increased hepatic glycogen storage, which is synergistically impaired by HFD 
and OLZ (Figure 5.2, panel B and Figure 5.3, panel A). 
 SFN does not affect apoptosis with HFD and OLZ, but greatly 3.
decreases lipid peroxidation 
Adducts of 4-HNE, which amassed in large quantity after HFD and OLZ 
exposure (see Chapter IV, Figure 4.4, panel A), appeared to nearly absent from 
the tissue sections of SFN-treated mice (Figure 5.3, panel B) .The visually 
apparent attenuation in staining was quantitated and determined to be a >20-fold 
decrease in 4-HNE binding. Apoptosis (as determined by TUNEL staining) was 
unaffected by SFN (Figure 5.3, panel C).   
D. Discussion 
Obesity and antipsychotic-induced dysmetabolism may both be mediated 




Whereas in obesity it is the reactive metabolites of sugars and lipids that may 
cause oxidative stress,131,132 atypical antipsychotics may reduce expression of 
antioxidant-encoding genes133 in addition to generating reactive metabolites.134  
Antipsychotics can also be considered secondary contributors to oxidative stress 
in that they promote obesity.  Although the exact presentation of oxidative stress 
in OLZ metabolism is not certain, it may be possible to prevent or treat the 
weight-related side effects of OLZ using antioxidants. 
In vitro, direct-acting antioxidants such as resveratrol consistently display 
the ability to neutralize reactive oxygen species (ROS) and reactive drug 
metabolites.135  In vivo, however, the success of antioxidant interventions has 
been difficult to replicate.68  The pharmacokinetic and pharmacodynamic 
limitations of direct-acting antioxidants like resveratrol may explain the 
incongruous in vitro and in vivo experimental outcomes.  Direct antioxidants are 
reactive species themselves, making it difficult to ensure that, in the intact 
organism, direct antioxidants reach the desired site of action before reacting with 
other biological molecules.  Agents like resveratrol and vitamin C are also prone 
to redox cycling, meaning that they will readily act as both a reductant and an 
oxidant in a complex living system.69  This means that in practice, high doses of 
direct antioxidants can contribute to the same problems that they are intended to 
solve.   
Indirect antioxidants do not usually participate in redox reactions and 
therefore offer an alternative approach to manage oxidative stress.  SFN is 




ROS.69  Here also, the indirect antioxidant sulforaphane was used successfully to 
prevent oxidative stress in a model of chronic high-fat diet and olanzapine 
administration.  No exacerbation of oxidative stress was noted.  The action of 
intrinsic cellular defense mechanisms by SFN therefore exemplifies an effective 
strategy to offset the side effects of antipsychotic treatment.  It should be 






Figure 5.1: Simplified model of Nrf2 induction by SFN 
 
SFN’s electrophilic side chain alkylates cysteine residues on Keap1.  The 
conformational change induced in Keap1 allows the release of its binding 
partner, Nrf2.  Unbound Nrf2 translocates to the nucleus and binds to antioxidant 
response elements in DNA.  See Discussion in section A of Chapter VI for 








Figure 5.2: Influence of SFN on the metabolic outcomes of HFD and OLZ 
co-administration 
 
Panel A: H&E staining is shown at 100x and 400x (inset). Panel B: Weight 
and other parameters were measured after HFD and OLZ treatment in the 
presence or absence of SFN. Values for the SFN treatment group are expressed 









Figure 5.3: Histological indices of protection from HFD and OLZ by SFN 
 
Livers sections from animals given HFD and OLZ were compared with 
liver sections from animals who were additionally co-administered SFN.  Staining 
for glycogen (panel A), lipid peroxidation (panel B), and apoptosis (panel C) was 










DISCUSSION AND CONCLUSIONS 
 
A. Biochemical pathways involved in NAFLD and/or OLZ toxicity and 
potential pharmacological interventions 
 AMPK 1.
One of the major regulators of energy homeostasis in mammalian cells is 
the 5' adenosine monophosphate-activated protein kinase (AMPK).113  The ratio 
of AMP:ATP is roughly proportional to cellular nutrient availability;136 therefore, 
AMPK’s ability to respond to changes in the AMP:ATP ratio makes it an 
important coordinator of various metabolic functions.  When AMPK’s α subunit is 
phosphorylated at threonine-172, the kinase is activated and promotes ATP-
generating catabolic processes, e.g., fatty acid oxidation.  It is through increased 
catabolism, in fact, that the AMPK-activating drug metformin is thought to reverse 
fatty liver and glucose intolerance.137    
Along with its well-established roles in energy homeostasis, research has 
also demonstrated a link between AMPK activation and atypical antipsychotics 
such as OLZ.  AMPK activation in the hypothalamus is frequently reported after 
OLZ administration, leading many researchers to consider its mechanistic 




shown in PC12 cells (i.e., non-neuronal cells) after OLZ exposure, demonstrating 
that AMPK activation with OLZ is not restricted to the CNS.140  Meltzer141 and 
others have suggested that AMPK activation may be inducing the metabolic side 
effects of OLZ.  It remains unclear, though, why AMPK activation by OLZ would 
promote symptoms of the metabolic syndrome when AMPK activation by 
metformin has clear antidiabetic effects.142  The moderate success of metformin 
in treating OLZ-induced diabetes has only further confounded the search for 
answers.143 
 mTOR 2.
The mammalian target of rapamycin (mTOR) is a widely-expressed 
serine-threonine kinase (see Tsang109 for review).  It is found as part of two 
functional complexes, mTORC1 and mTORC2, both of which are major 
mediators of cell growth and survival.  mTOR may be seen as a counterpart to 
AMPK: while AMPK is activated under conditions of nutrient depletion, mTOR is 
typically activated during times of adequate or surplus nutrient availability.144  The 
functions of mTOR, then, are mostly anabolic, including RNA transcription145 and 
adipogenesis.146  While some degree of mTOR activation is necessary, 
excessive activation of mTOR is implicated in obesity and diabetes.  Constitutive 
mTOR activation in vitro has been shown to impair insulin signaling.147  In further 
support of mTOR’s hypothesized role in metabolic disorders, a clinical study 
published just earlier this year reported that mTORC1 signaling is activated in 




There is no clear link between mTOR and atypical antipsychotic drug 
actions; however, they are connected by a wealth of circumstantial evidence.  
Among its numerous other functions the mTOR pathway regulates memory and 
synaptic plasticity.149  Deletion of Rictor, the mTORC2 binding partner, in a 
mouse model induces schizophrenia-like behaviors and abnormal 
neurotransmission.150  Rapamycin, the most extensively studied mTOR inhibitor, 
has been suggested as a potential treatment for mood disorders;151 at the same 
time, ketamine, a known mTOR inducer, demonstrably improved bipolar disorder 
in a handful of small clinical trials.152,153  There are still huge gaps in our 
knowledge of mTOR and neurological dysfunction.  At present, there are no 
FDA-approved treatments for mental illness or obesity that directly target mTOR. 
 Nrf2 3.
NF-E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor 
universally expressed in the cytosol of eukaryotic cells.154,155   In the presence of 
electrophiles or reactive oxygen species, Nrf2 is released from its repressor 
protein Keap1 and the ubiquitin ligase Cul3.156,157  Upon its release from Keap1 
and Cul3, Nrf2 moves to the nucleus, where it can then bind to response 
elements in DNA158 and influence antioxidant gene transcription.  Because 
reactive oxygen species are proposed culprits in many disease states,53-56 Nrf2-
inducing chemicals are being explored as therapeutic agents.69  Nrf2’s ability to 
upregulate expression of cytoprotective genes makes it a potentially important 




Nrf2 and mTOR are not usually considered as parts of a common 
pathway.  However, these pathways do intersect, most notably at the level of 
insulin signaling.159  The actions of rapamycin and the experimental Nrf2 inducer 
CDDO-Im also suggest cross-talk between the pathways: Nrf2-mutated lung 
cancer cells are responsive to rapamycin,160 while CDDO-Im inhibits insulin-
mediated mTOR phosphorylation.161   
B. Major findings of this dissertation 
It has been stated several times throughout this work that OLZ is an 
effective drug for treating psychiatric illnesses including schizophrenia and 
bipolar disorder.162,163  The benefits of OLZ are countermanded by side effects 
such as weight gain, glucose intolerance and dyslipidemia which impact not only 
psychiatric treatment compliance but also increase the health risks to patients.  
An improved understanding of OLZ actions in the peripheral tissues may 
therefore identify new approaches to increase the long-term safety and utility of 
this drug.  Experiments in Chapter III were performed to reveal and characterize 
the mechanism(s) of OLZ-induced toxicity.  In Chapter IV, the experiments of the 
previous chapter were expanded to ascertain possible interactions of OLZ and 
the typical Western diet.  The experiments in Chapter V tested SFN as an 
adjunct to OLZ administration.  Specific findings from each of these chapters are 
discussed in the next paragraphs.     
 OLZ simultaneously activates AMPK and mTOR 1.
As has been observed previously, OLZ administration increased body 




detectable increase in food consumption.  These data suggest that OLZ 
administration may directly alter energy usage in vivo.  Previous experiments 
from other laboratories have shown that OLZ administration dysregulates 
carbohydrate and lipid metabolism (see Coccurrello94 for review).  Indeed, here, 
OLZ administration caused a complex phenotypic alteration in hepatic 
carbohydrate metabolism.  OLZ administration increased glycolysis without an 
apparent increase in mitochondrial respiration (Figures 3.4 and 3.6) and favored 
glycogen depletion (Figures 3.4 and 3.7).  OLZ administration also caused a 
slight but significant glucose intolerance (Figure 3.7) and increased postprandial 
plasma glucose (Table 3.1).  A shift to an elevated, but incomplete (i.e., 
anaerobic), glycolysis would favor ATP generation from alternate sources, such 
as lipid oxidation.  In support of the hypothesized shift to glycolysis, OLZ 
administration increases plasma lactic acid levels in humans.94  Furthermore, 
Albaugh et al.104 demonstrated that OLZ administration lowers the respiratory 
exchange ratio (RER) in rats, indicative of a preferential shift to NEFA over 
carbohydrates as fuel.  These results are in line with the observation here that 
hepatic and plasma triglycerides were elevated by OLZ administration (Figure 3.3 
and Table 3.1), without a commensurate increase in hepatic NEFA (Figure 3.3).   
Within the cell, carbohydrate and lipid metabolism are usually under the 
tight control of the protein kinases AMPK and mTOR.  Both AMPK and mTOR 
are known to act as “sensors” of cellular energy status and help to maintain 
homeostasis.113,164  In general, the downstream effects of AMPK activation are 




Glycolysis, for example, is enhanced by AMPK.  Signaling downstream of AMPK 
also inhibits ATP-consuming processes.165  In contrast to AMPK, mTOR is 
activated during times of high nutrient availability and favors storage of excess 
nutrients (e.g., as triglycerides).  Activation of the mTOR pathway promotes ATP-
consuming processes such as protein and lipid synthesis through its downstream 
targets p70S6K and 4EBP1.  Earlier studies have demonstrated that AMPK is 
activated in the CNS by OLZ administration.140  Furthermore, OLZ increases 
p70S6K and 4EBP1 phosphorylation in cultured hepatocytes, indicative of mTOR 
activation.166  The experiments here demonstrate, for the first time, that OLZ in 
vivo concomitantly activates AMPK and mTOR pathways in the liver.  AMPK and 
mTOR are generally differentially activated and mediate opposing cellular 
functions. 144  The outcomes of OLZ administration on hepatic metabolism reflect, 
in part, these contradictory inputs.  These data suggest that treatment with OLZ 
results in a pseudo-fasted state wherein metabolic resources are abundant, but 
cannot be efficiently used.  The reason for OLZ’s concurrent activation of AMPK 
and mTOR is not immediately clear.  Should OLZ indeed induce a pseudo-fasted 
state, the activation of AMPK may be, in principle, via the classical accumulation 
of AMP.  
 OLZ modulates intracellular amino acid transport, which may affect 2.
energy homeostasis 
OLZ is reported elsewhere to modulate glutamine, glutamate and BCAA 
concentrations in brain and periphery, as well as key genes in glutamate 




acid changes is uncertain, but may be related to maintenance of the so-called 
“glutamate-glutamine cycle.”170-172  This is a model which proposes that 
excitatory neurotransmission is carefully maintained through the coordinated 
transport of glutamate and glutamine.  The cycle is neither closed nor 
stoichiometric173 but nonetheless finely synchronizes amino acid concentrations 
between  neuronal and non-neuronal compartments.  In the experiments 
presented here, OLZ administration modulated glutamate, glutamine, and leucine 
flux, while pathway analysis pointed to increases in the amino acid transporters 
LAT1, SNAT2, and EAAT3, among others.  The actions of OLZ seen here and in 
others’ work are consistent with the glutamatergic model of mental illness, which 
proposes that psychotic disorders are (at least partly) disorders of excitatory 
amino acid metabolism.123  Notably, hepatic mTOR activation is also mediated by 
these same fluctuations in amino acid metabolism.97,106,116,174-176  Meta-analyses 
have demonstrated that targeting AMPK with metformin confers a significant, 
albeit small, protective effect against some of the metabolic effects of OLZ.115  
However, targeting mTOR overactivation may be a more successful approach. 
 HFD aggravates liver injury caused by OLZ 3.
Another important aspect of this work is that the combination of HFD and 
OLZ administration significantly increased indices of liver injury (Figure 4.3) in 
mice.  Elevation of liver enzymes is described as a common reaction with OLZ 
administration, resulting in drug discontinuation.177  The pathologic changes in 
liver due to OLZ alone (Table 3.1 and Figure 4.3) are analogous to those caused 




and OLZ together was greater than the injury resulting from either factor on its 
own, possibly indicating that these factors mediate toxicity through separate, 
distinct mechanisms.  NAFLD is a spectrum of liver diseases, ranging from the 
relatively benign simple steatosis to hepatocellular carcinoma.27  Although the 
prevalence of simple steatosis in individuals at risk for NAFLD can be very high,46 
the prevalence of NASH is much lower in this population (~40%).46  These 
factors emphasize that the risk for developing more severe stages of NAFLD 
(i.e., NASH and beyond) is not based solely on obesity, but is rather mitigated by 
other factors.47,48  It is likely that OLZ treatment could be such a factor that 
enhances the progression of NAFLD.   
 SFN counteracts oxidative stress caused by HFD and OLZ 4.
Much of the research regarding Nrf2 has focused on the pathway’s 
function in mitigating oxidative stress.178  Though antioxidant defense is a 
primary feature of Nrf2 pathway induction, recent investigation shows that Nrf2 
also exerts regulatory effects on lipid metabolism.179 180  Moreover, because 
oxidative stress and altered lipid metabolism are both correlated with the side 
effects of OLZ, Nrf2 induction (using SFN) was tested as a method of minimizing 
these side effects.  
SFN, as predicted, offset many of the side effects of OLZ without causing 
apparent injury to the mice (Figure 5.2).  The most significant improvements seen 
were in weight, adiposity, and lipid peroxidation.  The favorable results with SFN 
suggest that Nrf2 induction may be used to decrease the incidence of additional 




administration might also encourage patient adherence with psychiatric treatment 
regimens. 
C. Strengths and weaknesses of this dissertation 
 Strengths 1.
There are many strengths of this dissertation.  One such strength is that it 
identifies a new mechanism in the development of metabolic dysregulation 
caused by OLZ.  It also offers additional evidence for the worsening of liver 
disease during antipsychotic administration and suggests a possible strategy for 
prevention.  The research presented in this text thus advances the ongoing 
search for better-tolerated pharmacological treatments for mental illness.  
Another strength of this dissertation is the use of whole animal models.  
Most of the experiments described here were performed in vivo, except where to 
do so would be impractical or impossible (e.g., measuring oxygen consumption in 
real time with multiple doses of OLZ).  Obesity and mental illness are both 
complex phenomena, not limited to one particular organ or cell type.  Also, like 
most psychiatric medications, OLZ is widely systemically distributed, as this is 
the most practical method of delivering the drug to the CNS.181  As such it is 
preferable to study the effects of OLZ in a complex, dynamic system such as an 
intact organism. 
 Weaknesses 2.
The use of animal models, while a strength, is also a potential weakness.  




studies, no animal model can completely recapitulate the human condition.  Apart 
from obvious differences in sleeping, eating, and social interactions, there is also 
no rodent model that exactly represents human mental illness182 or non-alcoholic 
liver disease progression from steatosis to NASH.61 
Another weakness of this study is that all conditions are not adequately 
represented in the SFN experiment.  The combination of OLZ and low-fat/control 
diet was not tested with SFN, nor was SFN administered in any diet group in the 
absence of OLZ.  Additionally, increased drug efflux is a known consequence of 
Nrf2 induction.183  More research will be needed to determine whether or not 
SFN is promoting OLZ removal and perhaps jeopardizing the therapeutic 
potential of OLZ.  
D. Future directions 
Research answers scientific questions, but just as often it creates new 
questions.  The following are future experiments that logically proceed from the 
findings of this dissertation: 
 What are the effects of combined HFD and OLZ exposure on AMPK 1.
and mTOR expression? 
Because the experiments described in Chapters IV and V were largely 
concerned with pathology and not biochemical mechanism of development, 
mTOR, AMPK, and related proteins in these signaling pathways were not 
measured in animals treated with HFD and/or SFN.  Obesity and high-fat diet by 




concomitant HFD and OLZ on mTOR regulation have not been explored.  
Likewise, the existence of a relationship between mTOR and Nrf2 is not firmly 
established; it would therefore be interesting to determine how mTOR signaling 
and expression are mediated with SFN alone, SFN in combination with HFD, and 
SFN with concurrent HFD and OLZ. 
 Does SFN influence absorption, distribution, metabolism, or 2.
excretion of OLZ? 
In the Weaknesses section of this chapter, it was mentioned that 
metabolic response to SFN was not observed in all possible conditions, i.e., with 
low-fat control diet or without OLZ.  While it is clear that SFN prevented weight 
gain and liver injury in the HFD + chronic OLZ model, it is not certain how SFN 
did this.  SFN is widely shown to prevent oxidative stress and is also understood 
to mediate lipid metabolism, but neither function of SFN was conclusively 
determined in any of the preceding experiments.  Perhaps even more 
importantly, it was not determined how SFN co-administration affects OLZ 
disposition.  For example, glucuronidation is recognized to be increased by SFN 
administration,185 which may suggest that SFN worked in this model simply by 
increasing OLZ excretion and removal.  As Bever and Perry1 noted in their 
review, OLZ is metabolized by many known mechanisms, so it is unlikely that a 
change in any one pathway would affect total clearance of OLZ.  Still, excessive 
clearance of OLZ should be ruled out in future experiments. 





The approved uses of OLZ are psychiatric disorders.  The most common 
off-label uses for OLZ are mental illness-related as well.  Naturally, much of the 
existing literature is devoted to the study of OLZ in central nervous system tissue.  
In order to gain a more complete understanding of how OLZ works, its effects 
should be more extensively studied in non-neuronal regions, both in the intact 
organism and in cell culture.  A prime candidate for future study is adipose tissue 
which, despite its known role as an arbiter of leptin secretion and CNS 
recognition of satiety,186 remains poorly investigated.  Skeletal muscle is also 
overlooked in antipsychotic research, even though myopathy is sometimes 
reported during OLZ administration to human patients,187 and should also be 
thoroughly investigated.   






 1.  Bever, K. A.; Perry, P. J. Olanzapine: a serotonin-dopamine-receptor 
antagonist for antipsychotic therapy. Am J Health Syst Pharm. 
1998, 55 (10), 1003-1016. 
 2.  Borison, R. L. Clinical efficacy of serotonin-dopamine antagonists relative 
to classic neuroleptics. J Clin Psychopharmacol. 1995, 15 (1 Suppl 
1), 24S-29S. 
 3.  Bymaster, F. P.; Calligaro, D. O.; Falcone, J. F.; Marsh, R. D.; Moore, N. 
A.; Tye, N. C.; Seeman, P.; Wong, D. T. Radioreceptor binding 
profile of the atypical antipsychotic olanzapine. 
Neuropsychopharmacology. 1996, 14 (2), 87-96. 
 4.  Moore, N. A.; Tye, N. C.; Axton, M. S.; Risius, F. C. The behavioral 
pharmacology of olanzapine, a novel "atypical" antipsychotic agent. 
J Pharmacol Exp. Ther. 1992, 262 (2), 545-551. 
 5.  Edlinger, M.; Baumgartner, S.; Eltanaihi-Furtmuller, N.; Hummer, M.; 
Fleischhacker, W. Switching between second-generation 
antipsychotics: why and how? CNS Drugs. 2005, 19 (1), 27-42. 
 6.  Tran, P. V.; Hamilton, S. H.; Kuntz, A. J.; Potvin, J. H.; Andersen, S. W.; 
Beasley, C., Jr.; Tollefson, G. D. Double-blind comparison of 
olanzapine versus risperidone in the treatment of schizophrenia 
and other psychotic disorders. J Clin Psychopharmacol. 1997, 17 
(5), 407-418. 
 7.  Stubner, S.; Grohmann, R.; Engel, R.; Bandelow, B.; Ludwig, W. D.; 
Wagner, G.; Muller-Oerlinghausen, B.; Moller, H. J.; Hippius, H.; 
Ruther, E. Blood dyscrasias induced by psychotropic drugs. 
Pharmacopsychiatry. 2004, 37 Suppl 1:S70-8., S70-S78. 
 8.  Maher, A. R.; Theodore, G. Summary of the comparative effectiveness 
review on off-label use of atypical antipsychotics. J Manag Care 




 9.  Fountoulakis, K. N.; Nimatoudis, I.; Iacovides, A.; Kaprinis, G. Off-label 
indications for atypical antipsychotics: A systematic review. Ann. 
Gen. Hosp. Psychiatry. 2004, 3 (1), 4. 
 10.  Mathews, M.; Muzina, D. J. Atypical antipsychotics: new drugs, new 
challenges. Cleve Clin J Med. 2007, 74 (8), 597-606. 
 11.  Ader, M.; Kim, S. P.; Catalano, K. J.; Ionut, V.; Hucking, K.; Richey, J. M.; 
Kabir, M.; Bergman, R. N. Metabolic dysregulation with atypical 
antipsychotics occurs in the absence of underlying disease: a 
placebo-controlled study of olanzapine and risperidone in dogs. 
Diabetes. 2005, 54 (3), 862-871. 
 12.  Vidarsdottir, S.; de Leeuw van Weenen JE; Frolich, M.; Roelfsema, F.; 
Romijn, J. A.; Pijl, H. Effects of olanzapine and haloperidol on the 
metabolic status of healthy men. J Clin Endocrinol Metab. 2010, 95 
(1), 118-125. 
 13.  Allison, D. B.; Casey, D. E. Antipsychotic-induced weight gain: a review of 
the literature. J Clin Psychiatry 2001, 62 (Suppl 7), 22-31. 
 14.  Citrome, L.; Holt, R. I.; Walker, D. J.; Hoffmann, V. P. Weight gain and 
changes in metabolic variables following olanzapine treatment in 
schizophrenia and bipolar disorder. Clin Drug Investig. 2011, 31 (7), 
455-482. 
 15.  Eli Lilly and Company Highlights of prescribing information. pi. lilly. 
com/us/zyprexa-pi. pdf 2011. 
 16.  Weiden, P. J.; Mackell, J. A.; McDonnell, D. D. Obesity as a risk factor for 
antipsychotic noncompliance. Schizophr Res. 2004, 66 (1), 51-57. 
 17.  Baptista, T.; Zarate, J.; Joober, R.; Colasante, C.; Beaulieu, S.; Paez, X.; 
Hernandez, L. Drug induced weight gain, an impediment to 
successful pharmacotherapy: focus on antipsychotics. Curr Drug 
Targets. 2004, 5 (3), 279-299. 
 18.  Mojtabai, R.; Lavelle, J.; Gibson, P. J.; Bromet, E. J. Atypical 
antipsychotics in first admission schizophrenia: medication 
continuation and outcomes. Schizophr Bull. 2003, 29 (3), 519-530. 
 19.  Dilla, T.; Ciudad, A.; Alvarez, M. Systematic review of the economic 
aspects of nonadherence to antipsychotic medication in patients 
with schizophrenia. Patient. Prefer. Adherence. 2013, 7:275-84. 
doi: 10.2147/PPA.S41609. Print;%2013., 275-284. 
 20.  Weiden, P. J.; Olfson, M. Cost of relapse in schizophrenia. Schizophr Bull. 




 21.  Swinburn, B. A.; Sacks, G.; Hall, K. D.; McPherson, K.; Finegood, D. T.; 
Moodie, M. L.; Gortmaker, S. L. The global obesity pandemic: 
shaped by global drivers and local environments. Lancet 2011, 378 
(9793), 826-837. 
 22.  Flegal, K. M.; Carroll, M. D.; Ogden, C. L.; Curtin, L. R. Prevalence and 
trends in obesity among US adults, 1999-2008. JAMA. 2010, 303 
(3), 235-241. 
 23.  Flegal, K. M.; Carroll, M. D.; Kuczmarski, R. J.; Johnson, C. L. Overweight 
and obesity in the United States: prevalence and trends, 1960-
1994. Int. J. Obes. Relat Metab Disord. 1998, 22 (1), 39-47. 
 24.  Bhala, N.; Angulo, P.; van der Poorten, D.; Lee, E.; Hui, J. M.; Saracco, 
G.; Adams, L. A.; Charatcharoenwitthaya, P.; Topping, J. H.; 
Bugianesi, E.; Day, C. P.; George, J. The natural history of 
nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: 
an international collaborative study. Hepatology. 2011, 54 (4), 
1208-1216. 
 25.  Ludwig, J.; Viggiano, T. R.; McGill, D. B.; Oh, B. J. Nonalcoholic 
steatohepatitis: Mayo Clinic experiences with a hitherto unnamed 
disease. Mayo Clin. Proc. 1980, 55 (7), 434-438. 
 26.  Day, C. P. Non-alcoholic fatty liver disease: current concepts and 
management strategies. Clin. Med. 2006, 6 (1), 19-25. 
 27.  Ratziu, V.; Bonyhay, L.; Di, M., V; Charlotte, F.; Cavallaro, L.; Sayegh-
Tainturier, M. H.; Giral, P.; Grimaldi, A.; Opolon, P.; Poynard, T. 
Survival, liver failure, and hepatocellular carcinoma in obesity-
related cryptogenic cirrhosis. Hepatology. 2002, 35 (6), 1485-1493. 
 28.  Masuoka, H. C.; Chalasani, N. Nonalcoholic fatty liver disease: an 
emerging threat to obese and diabetic individuals. Ann. N. Y. Acad 
Sci. 2013, 1281:106-22. doi: 10.1111/nyas.12016. Epub;%2013 
Jan 30., 106-122. 
 29.  Lazo, M.; Hernaez, R.; Eberhardt, M. S.; Bonekamp, S.; Kamel, I.; Guallar, 
E.; Koteish, A.; Brancati, F. L.; Clark, J. M. Prevalence of 
Nonalcoholic Fatty Liver Disease in the United States: The Third 
National Health and Nutrition Examination Survey, 1988-1994. Am 
J Epidemiol. 2013. 
 30.  Ogden, C. L.; Carroll, M. D.; Curtin, L. R.; McDowell, M. A.; Tabak, C. J.; 
Flegal, K. M. Prevalence of overweight and obesity in the United 




 31.  Heiskanen, T.; Niskanen, L.; Lyytikainen, R.; Saarinen, P. I.; Hintikka, J. 
Metabolic syndrome in patients with schizophrenia. J Clin 
Psychiatry. 2003, 64 (5), 575-579. 
 32.  Allison, D. B.; Newcomer, J. W.; Dunn, A. L.; Blumenthal, J. A.; 
Fabricatore, A. N.; Daumit, G. L.; Cope, M. B.; Riley, W. T.; 
Vreeland, B.; Hibbeln, J. R.; Alpert, J. E. Obesity among those with 
mental disorders: a National Institute of Mental Health meeting 
report. Am J Prev. Med. 2009, 36 (4), 341-350. 
 33.  Dickerson, F. B.; Brown, C. H.; Kreyenbuhl, J. A.; Fang, L.; Goldberg, R. 
W.; Wohlheiter, K.; Dixon, L. B. Obesity among individuals with 
serious mental illness. Acta Psychiatr Scand. 2006, 113 (4), 306-
313. 
 34.  Haberfellner, E. M.; Honsig, T. Nonalcoholic steatohepatitis: a possible 
side effect of atypical antipsychotics. J Clin Psychiatry. 2003, 64 
(7), 851. 
 35.  Arulmozhi, D. K.; Dwyer, D. S.; Bodhankar, S. L. Antipsychotic induced 
metabolic abnormalities: an interaction study with various PPAR 
modulators in mice. Life Sci. 2006, 79 (19), 1865-1872. 
 36.  Chintoh, A. F.; Mann, S. W.; Lam, L.; Lam, C.; Cohn, T. A.; Fletcher, P. J.; 
Nobrega, J. N.; Giacca, A.; Remington, G. Insulin resistance and 
decreased glucose-stimulated insulin secretion after acute 
olanzapine administration. J Clin Psychopharmacol. 2008, 28 (5), 
494-499. 
 37.  McElroy, S. L. Obesity in patients with severe mental illness: overview and 
management. J Clin Psychiatry. 2009, 70 Suppl 3:12-21. doi: 
10.4088/JCP.7075su1c.03., 12-21. 
 38.  Langhans, W. Role of the liver in the control of glucose-lipid utilization and 
body weight. Curr Opin Clin Nutr Metab Care. 2003, 6 (4), 449-455. 
 39.  Fabbrini, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver 
disease: biochemical, metabolic, and clinical implications. 
Hepatology. 2010, 51 (2), 679-689. 
 40.  Aravagiri, M.; Teper, Y.; Marder, S. R. Pharmacokinetics and tissue 
distribution of olanzapine in rats. Biopharm. Drug Dispos. 1999, 20 
(8), 369-377. 
 41.  Sandoval, D. A.; Obici, S.; Seeley, R. J. Targeting the CNS to treat type 2 




 42.  Weston-Green, K.; Huang, X. F.; Deng, C. Alterations to 
melanocortinergic, GABAergic and cannabinoid neurotransmission 
associated with olanzapine-induced weight gain. PLoS One. 2012, 
7 (3), e33548. 
 43.  Grayson, B. E.; Seeley, R. J.; Sandoval, D. A. Wired on sugar: the role of 
the CNS in the regulation of glucose homeostasis. Nat Rev 
Neurosci. 2013, 14 (1), 24-37. 
 44.  Girault, E. M.; Alkemade, A.; Foppen, E.; Ackermans, M. T.; Fliers, E.; 
Kalsbeek, A. Acute peripheral but not central administration of 
olanzapine induces hyperglycemia associated with hepatic and 
extra-hepatic insulin resistance. PLoS One. 2012, 7 (8), e43244. 
 45.  Chintoh, A. F.; Mann, S. W.; Lam, T. K.; Giacca, A.; Remington, G. Insulin 
resistance following continuous, chronic olanzapine treatment: An 
animal model. Schizophr Res. 2008, 104, 23-30. 
 46.  Machado, M.; Marques-Vidal, P.; Cortez-Pinto, H. Hepatic histology in 
obese patients undergoing bariatric surgery. J. Hepatol. 2006, 45 
(4), 600-606. 
 47.  Day, C. P.; James, O. F. Steatohepatitis: a tale of two "hits"? 
Gastroenterology. 1998, 114 (4), 842-845. 
 48.  Yang, S. Q.; Lin, H. Z.; Lane, M. D.; Clemens, M.; Diehl, A. M. Obesity 
increases sensitivity to endotoxin liver injury: implications for the 
pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997, 
94, 2557-2562. 
 49.  Kregel, K. C.; Zhang, H. J. An integrated view of oxidative stress in aging: 
basic mechanisms, functional effects, and pathological 
considerations. Am J Physiol Regul. Integr. Comp Physiol. 2007, 
292 (1), R18-R36. 
 50.  Arteel, G. E. Oxidants and antioxidants in alcohol-induced liver disease. 
Gastroenterology 2003, 124 (3), 778-790. 
 51.  Pi, J.; Zhang, Q.; Fu, J.; Woods, C.; Hou, Y.; Corkey, B.; Collins, S.; 
Andersen, M. ROS signaling, oxidative stress and Nrf2 in 
pancreatic beta-cell function. Tox. Appl. Pharmacol. 2010, 244 (1), 
77-83. 





 53.  Klaasen, C. D.; Reisman, S. A. Nrf2 the rescue: Effects of the 
antioxidative/electrophilic response on the liver. Tox. Appl. 
Pharmacol. 2010, 244, 57-65. 
 54.  Maher, J.; Yamamoto, M. The rise of antioxidant signaling--the evolution 
and hormetic actions of Nrf2. Toxicol. Appl Pharmacol. 2010, 244 
(1), 4-15. 
 55.  Kensler, T. W.; Wakabayashi, N.; Biswal, S. Cell survival responses to 
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. 
Rev Pharmacol Toxicol. 2007, 47:89-116., 89-116. 
 56.  Kohen, R.; Nyska, A. Oxidation of biological systems: oxidative stress 
phenomena, antioxidants, redox reactions, and methods for their 
quantification. Toxicol. Pathol. 2002, 30 (6), 620-650. 
 57.  Ohara, Y.; Peterson, T. E.; Harrison, D. G. Hypercholesterolemia 
Increases Endothelial Superoxide Anion Production. J Clin Invest 
1993, 91, 2546-2551. 
 58.  Inoguchi, T.; Li, P.; Umeda, F.; Yu, H. Y.; Kakimoto, M.; Imamura, M.; 
Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; Sano, H.; Utsumi, H.; 
Nawata, H. High Glucose Level and Free Fatty Acid Stimulate 
Reactive Oxygen Species Production Through Protein Kinase C-
Dependent Activation of NAD(P)H Oxidase in Cultured Vascular 
Cells. Diabetes 2000, 49, 1939-1945. 
 59.  Brownlee, M. Biochemistry and molecular cell biology of diabetic 
complications. Nature 2001, 414, 813-820. 
 60.  Pessayre, D.; Fromenty, B. NASH: a mitochondrial disease. J. Hepatol. 
2005, 42, 928-940. 
 61.  Browning, J. D.; Horton, J. D. Molecular mediators of hepatic steatosis 
and liver injury. J Clin Invest 2004, 114 (2), 147-152. 
 62.  Padurariu, M.; Ciobica, A.; Dobrin, I.; Stefanescu, C. Evaluation of 
antioxidant enzymes activities and lipid peroxidation in 
schizophrenic patients treated with typical and atypical 
antipsychotics. Neurosci. Lett. 2010, 479 (3), 317-320. 
 63.  Lu, S. C. Antioxidants in the treatment of chronic liver diseases: why is the 
efficacy evidence so weak in humans? Hepatology 2008, 48 (5), 
1359-1361. 
 64.  Podmore, I.; Griffiths, H.; Herbert, K.; Mistry, N.; Mistry, P.; Lunec, J. 




 65.  Paolini, M.; Pozzetti, L.; Pedulli, G. F.; Marchesi, E.; Cantelli-Forti, G. The 
Nature of Prooxidant Activity of Vitamin C. Life Sci. 1999, 64 (23), 
273-278. 
 66.  Miller, E. R. 3.; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.; Appel, L. J.; 
Guallar, E. Meta-analysis: high-dosage vitamin E supplementation 
may increase all-cause mortality. Ann. Intern. Med. 2005, 142 (1), 
37-46. 
 67.  Sies, H. Strategies of antioxidant defense. Eur. J. Biochem. 1993, 215, 
213-219. 
 68.  Steinhubl, S. R. Why Have Antioxidants Failed in Clinical Trials? Am J 
Cardiol 2008, 101 (10A), 14D-19D. 
 69.  Dinkova-Kostova, A. T.; Talalay, P. Direct and indirect antioxidant 
properties of inducers of cytoprotective proteins. Mol. Nutr. Food 
Res. 2008, 52, S128-S138. 
 70.  Fahey, J. W.; Talalay, P. Antioxidant functions of sulforaphane: a potent 
inducer of Phase II detoxication enzymes. Food Chem. Toxicol. 
1999, 37 (9-10), 973-979. 
 71.  Juge, N.; Mithen, R. F.; Traka, M. Molecular basis for chemoprevention by 
sulforaphane: a comprehensive review. Cell. Mol. Life Sci. 2007, 64 
(9), 1105-1127. 
 72.  Salmasi, F. B.; Jazayeri, M.; Ghaeli, P.; Hashemian, F.; Akhondzadeh, S.; 
Raisi, F.; Hosseini, S. H.; Setareh, M. J.; Khavidaki, S. D. 
Comparing the effects of high-dose vitamin E with those of placebo 
on insulin resistance in patients with schizophrenia treated with 
olanzapine. J Clin Psychopharmacol. 2009, 29 (2), 182-183. 
 73.  Westerlund, C.; Ostlund-Lindqvist, A. M.; Sainsbury, M.; Shertzer, H. G.; 
Sjoquist, P. O. Characterization of novel indenoindoles. Part I. 
Structure-activity relationships in different model systems of lipid 
peroxidation. Biochem Pharmacol. 1996, 51 (10), 1397-1402. 
 74.  Shertzer, H.; Kendig, E.; Nasrallah, H.; Johansson, E.; Genter, M. 
Protection from olanzapine-induced metabolic toxicity in mice by 
acetaminophen and tetrahydroindenoindole. Int J Obes 2010, 34 
(6), 970-979. 
 75.  Mas, S.; Gasso, P.; Trias, G.; Bernardo, M.; Lafuente, A. Sulforaphane 
protects SK-N-SH cells against antipsychotic-induced oxidative 




 76.  Kozul, C. D.; Nomikos, A. P.; Hampton, T. H.; Warnke, L. A.; Gosse, J. A.; 
Davey, J. C.; Thorpe, J. E.; Jackson, B. P.; Ihnat, M. A.; Hamilton, 
J. W. Laboratory diet profoundly alters gene expression and 
confounds genomic analysis in mouse liver and lung. Chem. Biol. 
Interact. 2008, 173 (2), 129-140. 
 77.  Kapur, S.; VanderSpek, S. C.; Brownlee, B. A.; Nobrega, J. N. 
Antipsychotic dosing in preclinical models is often unrepresentative 
of the clinical condition: a suggested solution based on in vivo 
occupancy. J Pharmacol Exp. Ther. 2003, 305 (2), 625-631. 
 78.  McDonnell, D. P.; Kryzhanovskaya, L. A.; Zhao, F.; Detke, H. C.; 
Feldman, P. D. Comparison of metabolic changes in patients with 
schizophrenia during randomized treatment with intramuscular 
olanzapine long-acting injection versus oral olanzapine. Hum 
Psychopharmacol. 2011, 26 (6), 422-433. 
 79.  van der Zwaal, E. M.; Luijendijk, M. C.; Adan, R. A.; la Fleur, S. E. 
Olanzapine-induced weight gain: chronic infusion using osmotic 
minipumps does not result in stable plasma levels due to 
degradation of olanzapine in solution. Eur J Pharmacol. 2008, 585 
(1), 130-136. 
 80.  Salamone, L. M.; Fuerst, T.; Kern, M.; Lang, T.; Dockrell, M.; Cauley, J. 
A.; Nevitt, M.; Tylavsky, F.; Lohman, T. G. Measurement of fat 
mass using DEXA: a validation study in elderly adults. J Appl 
Physiol. 2000, 89 (1), 345-352. 
 81.  Andrikopoulos, S.; Blair, A. R.; Deluca, N.; Fam, B. C.; Proietto, J. 
Evaluating the glucose tolerance test in mice. Am J Physiol 
Endocrinol Metab. 2008, 295 (6), E1323-E1332. 
 82.  Bligh, E. G.; Dyer, W. J. A rapid method of total lipid extraction and 
purification. Can. J. Biochem. Physiol. 1959, 37, 911-917. 
 83.  Arteel, G. E.; Iimuro, Y.; Yin, M.; Raleigh, J. A.; Thurman, R. G. Chronic 
enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. 
Hepatology 1997, 25 (4), 920-926. 
 84.  Arteel, G. E.; Gaebele, E.; Wheeler, M. D.; Uesugi, T.; Kadiiska, M.; 
Connor, H. D.; Mason, R. P.; Thurman, R. G. Inducible nitric oxide 
synthase is necessary for alcohol-induced liver injury: studies with 
knock-out mice. Hepatology 2003, , . 
 85.  von Montfort, C.; Beier, J. I.; Guo, L.; Kaiser, J. P.; Arteel, G. E. 
Contribution of the sympathetic hormone epinephrine to the 




Am. J. Physiol Gastrointest. Liver Physiol. 2008, 294 (5), G1227-
G1234. 
 86.  SEIFTER, S.; DAYTON, S.; Novic, B.; Muntwyler, E. The estimation of 
glycogen with the anthrone reagent. Arch Biochem. 1950, 25 (1), 
191-200. 
 87.  Leyva, A.; Quintana, A.; Sanchez, M.; Rodriguez, E. N.; Cremata, J.; 
Sanchez, J. C. Rapid and sensitive anthrone-sulfuric acid assay in 
microplate format to quantify carbohydrate in biopharmaceutical 
products: method development and validation. Biologicals. 2008, 36 
(2), 134-141. 
 88.  Warburg, O.; Geissler, A. W.; Lorenz, S. Uber Wachstum von Krebszellen 
in Medien, deren Glucose durch Galaktose ersetzt ist. Hoppe 
Seylers. Z Physiol Chem. 1967, 348 (12), 1686-1687. 
 89.  Wei, X.; Shi, X.; Koo, I.; Kim, S.; Schmidt, R. H.; Arteel, G. E.; Watson, W. 
H.; McClain, C.; Zhang, X. MetPP: a computational platform for 
comprehensive two-dimensional gas chromatography time-of-flight 
mass spectrometry-based metabolomics. Bioinformatics. 2013. 
 90.  Zhang, J.; Fang, A.; Wang, B.; Kim, S. H.; Bogdanov, B.; Zhou, Z.; 
McClain, C.; Zhang, X. iMatch: a retention index tool for analysis of 
gas chromatography-mass spectrometry data. J Chromatogr. A. 
2011, 1218 (37), 6522-6530. 
 91.  Cope, M. B.; Nagy, T. R.; Fernandez, J. R.; Geary, N.; Casey, D. E.; 
Allison, D. B. Antipsychotic drug-induced weight gain: development 
of an animal model. Int J Obes 2005, 29, 607-614. 
 92.  Hroudova, J.; Fisar, Z. Activities of respiratory chain complexes and citrate 
synthase influenced by pharmacologically different antidepressants 
and mood stabilizers. Neuroendocrinology Letters 2010, 31 (3), 
336-342. 
 93.  Marroquin, L. D.; Hynes, J.; Dykens, J. A.; Jamieson, J. D.; Will, Y. 
Circumventing the Crabtree effect: replacing media glucose with 
galactose increases susceptibility of HepG2 cells to mitochondrial 
toxicants. Toxicol. Sci. 2007, 97 (2), 539-547. 
 94.  Coccurello, R.; Moles, A. Potential mechanisms of atypical antipsychotic-
induced metabolic derangement: Clues for understanding obesity 
and novel drug design. Pharmacol Therapeut. 2010, 127, 210-251. 
 95.  Hampson, L. J.; Mackin, P.; Agius, L. Stimulation of glycogen synthesis 




mechanisms, and counter-regulation by atypical antipsychotic 
drugs. Diabetologia. 2007, 50 (8), 1743-1751. 
 96.  Göhring, I.; Mulder, H. Glutamate dehydrogenase, insulin secretion, and 
type 2 diabetes: a new means to protect the pancreatic -cell? J 
Endocrinol. 2012, 212 (3), 239-242. 
 97.  Nicklin, P.; Bergman, P.; Zhang, B.; Triantafellow, E.; Wang, H.; Nyfeler, 
B.; Yang, H.; Hild, M.; Kung, C.; Wilson, C.; Myer, V. E.; 
MacKeigan, J. P.; Porter, J. A.; Wang, Y. K.; Cantley, L. C.; Finan, 
P. M.; Murphy, L. O. Bidirectional transport of amino acids 
regulates mTOR and autophagy. Cell. 2009, 136 (3), 521-534. 
 98.  Evans, K.; Nasim, Z.; Brown, J.; Butler, H.; Kauser, S.; Varoqui, H.; 
Erickson, J. D.; Herbert, T. P.; Bevington, A. Acidosis-sensing 
glutamine pump SNAT2 determines amino acid levels and 
mammalian target of rapamycin signalling to protein synthesis in L6 
muscle cells. J Am Soc Nephrol. 2007, 18 (5), 1426-1436. 
 99.  Fuchs, B. C.; Bode, B. P. Amino acid transporters ASCT2 and LAT1 in 
cancer: partners in crime? Semin. Cancer Biol. 2005, 15 (4), 254-
266. 
 100.  Almilaji, A.; Pakladok, T.; Guo, A.; Munoz, C.; Foller, M.; Lang, F. 
Regulation of the glutamate transporter EAAT3 by mammalian 
target of rapamycin mTOR. Biochem Biophys Res Commun. 2012, 
421 (2), 159-163. 
 101.  Goff, D. C.; Hennen, J.; Lyoo, I. K.; Tsai, G.; Wald, L. L.; Evins, A. E.; 
Yurgelun-Todd, D. A.; Renshaw, P. F. Modulation of brain and 
serum glutamatergic concentrations following a switch from 
conventional neuroleptics to olanzapine. Biol Psychiatry. 2002, 51 
(6), 493-497. 
 102.  van der Heijden, F. M.; Fekkes, D.; Tuinier, S.; Sijben, A. E.; Kahn, R. S.; 
Verhoeven, W. M. Amino acids in schizophrenia: evidence for lower 
tryptophan availability during treatment with atypical 
antipsychotics? J Neural Transm. 2005, 112 (4), 577-585. 
 103.  Yudkoff, M.; Daikhin, Y.; Nissim, I.; Horyn, O.; Luhovyy, B.; Lazarow, A.; 
Nissim, I. Brain amino acid requirements and toxicity: the example 
of leucine. J Nutr. 2005, 135 (6 Suppl), 1531S-1538S. 
 104.  Albaugh, V. L.; Vary, T. C.; Ilkayeva, O.; Wenner, B. R.; Maresca, K. P.; 
Joyal, J. L.; Breazeale, S.; Elich, T. D.; Lang, C. H.; Lynch, C. J. 
Atypical antipsychotics rapidly and inappropriately switch peripheral 
fuel utilization to lipids, impairing metabolic flexibility in rodents. 




 105.  Dodd, K. M.; Tee, A. R. Leucine and mTORC1: a complex relationship. 
Am J Physiol Endocrinol Metab. 2012, 302 (11), E1329-E1342. 
 106.  Fox, H. L.; Pham, P. T.; Kimball, S. R.; Jefferson, L. S.; Lynch, C. J. 
Amino acid effects on translational repressor 4E-BP1 are mediated 
primarily by L-leucine in isolated adipocytes. Am J Physiol. 1998, 
275 (5 Pt 1), C1232-C1238. 
 107.  Krause, U.; Bertrand, L.; Hue, L. Control of p70 ribosomal protein S6 
kinase and acetyl-CoA carboxylase by AMP-activated protein 
kinase and protein phosphatases in isolated hepatocytes. Eur J 
Biochem. 2002, 269 (15), 3751-3759. 
 108.  Chan, M. K.; Tsang, T. M.; Harris, L. W.; Guest, P. C.; Holmes, E.; Bahn, 
S. Evidence for disease and antipsychotic medication effects in 
post-mortem brain from schizophrenia patients. Mol Psychiatry. 
2011, 16 (12), 1189-1202. 
 109.  Tsang, C. K.; Qi, H.; Liu, L. F.; Zheng, X. F. Targeting mammalian target 
of rapamycin (mTOR) for health and diseases. Drug Discov. Today. 
2007, 12 (3-4), 112-124. 
 110.  Rosner, M.; Siegel, N.; Valli, A.; Fuchs, C.; Hengstschläger, M. mTOR 
phosphorylated at S2448 binds to raptor and rictor. Amino Acids. 
2010, 38 (1), 223-228. 
 111.  Hara, H.; Yonezawa, K.; Kozlowski, M. T.; Sugimoto, T.; Andrabi, K.; 
Weng, Q. P.; Kasuga, M.; Nishimoto, I.; Avruch, J. Regulation of 
eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997, 272 
(42), 26457-26463. 
 112.  Guertin, D. A.; Stevens, D. M.; Thoreen, C. C.; Burds, A. A.; Kalaany, N. 
Y.; Moffat, J.; Brown, M.; Fitzgerald, K. J.; Sabatini, D. M. Ablation 
in mice of the mTORC components raptor, rictor, or mLST8 reveals 
that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, 
but not S6K1. Dev Cell. 2006, 11 (6), 859-871. 
 113.  Hardie, D. G. AMP-activated/SNF1 protein kinases: conserved guardians 
of cellular energy. Nat Rev Mol Cell Biol. 2008, 8 (10), 774-785. 
 114.  Coccurello, R.; Moles, A. A murine model of atypical antipsychotic-induced 
weight gain and metabolic dysregulation. 2010; p 9.33.1-9.33.22. 
 115.  Ehret, M.; Goethe, J.; Lanosa, M.; Coleman, C. I. The effect of metformin 
on anthropometrics and insulin resistance in patients receiving 
atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 




 116.  Laplante, M.; Sabatini, D. M. mTOR signaling in growth control and 
disease. Cell. 2012, 149 (2), 274-293. 
 117.  Xu, G.; Wang, Z.; Li, Y.; Li, Z.; Tang, H.; Zhao, J.; Xiang, X.; Ding, L.; Ma, 
L.; Yuan, F.; Fei, J.; Wang, W.; Wang, N.; Guan, Y.; Tang, C.; 
Mulholland, M.; Zhang, W. Ghrelin contributes to derangements of 
glucose metabolism induced by rapamycin in mice. Diabetologia. 
2012, 55 (6), 1813-1823. 
 118.  Aggarwal, D.; Fernandez, M. L.; Soliman, G. A. Rapamycin, an mTOR 
inhibitor, disrupts triglyceride metabolism in guinea pigs. 
Metabolism. 2006, 55 (6), 794-802. 
 119.  Zhao, L.; Ding, T.; Cyrus, T.; Cheng, Y.; Tian, H.; Ma, M.; Falotico, R.; 
Pratico, D. Low-dose oral sirolimus reduces atherogenesis, 
vascular inflammation and modulates plaque composition in mice 
lacking the LDL receptor. Br J Pharmacol. 2009, 156 (5), 774-785. 
 120.  Chang, G. R.; Chiu, Y. S.; Wu, Y. Y.; Chen, W. Y.; Liao, J. W.; Chao, T. 
H.; Mao, F. C. Rapamycin protects against high fat diet-induced 
obesity in C57BL/6J mice. J Pharmacol Sci. 2009, 109 (4), 496-
503. 
 121.  Neef, M.; Ledermann, M.; Saegesser, H.; Schneider, V.; Reichen, J. Low-
dose oral rapamycin treatment reduces fibrogenesis, improves liver 
function, and prolongs survival in rats with established liver 
cirrhosis. J Hepatol. 2006, 45 (6), 786-796. 
 122.  Foster, D. A.; Toschi, A. Targeting mTOR with rapamycin: one dose does 
not fit all. Cell Cycle. 2009, 8 (7), 1026-1029. 
 123.  Tsai, G.; Coyle, J. T. Glutamatergic mechanisms in schizophrenia. Annu. 
Rev Pharmacol Toxicol. 2002, 42:165-79., 165-179. 
 124.  Bechara, C. I.; Goldman-Levine, J. D. Dramatic worsening of type II 
diabetes mellitus due to olanzapine after 3 years of therapy. 
Pharmacotherapy. 2001, 21 (11), 1444-1447. 
 125.  Tschoner, A.; Engl, J.; Laimer, M.; Kaser, S.; Rettenbacher, M.; 
Fleischhacker, W. W.; Patsch, J. R.; Ebenbichler, C. F. Metabolic 
side effects of antipsychotic medication. Int J Clin Pract. 2007, 61 
(8), 1356-1370. 
 126.  Beier, J. I.; Luyendyk, J. P.; Guo, L.; von Montfort, C.; Staunton, D. E.; 
Arteel, G. E. Fibrin accumulation plays a critical role in the 
sensitization to lipopolysaccharide-induced liver injury caused by 




 127.  Plosker, G. L. Quetiapine: a pharmacoeconomic review of its use in 
bipolar disorder. Pharmacoeconomics. 2012, 30 (7), 611-631. 
 128.  McIntyre, R. S.; Leiter, L.; Yale, J. F.; CSPQ, M. D.; Lau, D.; Stip, E.; 
CSPQ, M. M.; Ur11, E.; Marie, J. e.; CPMSQ, M. F. Schizophrenia, 
glycemia and antipsychotic medications: an expert consensus 
review. Can J Diabetes 2005, 29, 113-121. 
 129.  Fimognari, C.; Lenzi, M.; Hrelia, P. Interaction of the isothiocyanate 
sulforaphane with drug disposition and metabolism: 
pharmacological and toxicological implications. Curr Drug Metab. 
2008, 9 (7), 668-678. 
 130.  Loignon, M.; Miao, W.; Hu, L.; Bier, A.; Bismar, T. A.; Scrivens, P. J.; 
Mann, K.; Basik, M.; Bouchard, A.; Fiset, P. O.; Batist, Z.; Batist, G. 
Cul3 overexpression depletes Nrf2 in breast cancer and is 
associated with sensitivity to carcinogens, to oxidative stress, and 
to chemotherapy. Mol Cancer Ther. 2009, 8 (8), 2432-2440. 
 131.  Dandona, P.; Ghanim, H.; Chaudhuri, A.; Dhindsa, S.; Kim, S. S. 
Macronutrient intake induces oxidative and inflammatory stress: 
potential relevance to atherosclerosis and insulin resistance. Exp. 
Mol Med. 2010, 42 (4), 245-253. 
 132.  Brown, L. A.; Kerr, C. J.; Whiting, P.; Finer, N.; McEneny, J.; Ashton, T. 
Oxidant stress in healthy normal-weight, overweight, and obese 
individuals. Obesity. (Silver. Spring). 2009, 17 (3), 460-466. 
 133.  Schmidt, A. J.; Hemmeter, U. M.; Krieg, J. C.; Vedder, H.; Heiser, P. 
Impact of haloperidol and quetiapine on the expression of genes 
encoding antioxidant enzymes in human neuroblastoma SH-SY5Y 
cells. J Psychiatr Res. 2009, 43 (8), 818-823. 
 134.  Heiser, P.; Sommer, O.; Schmidt, A. J.; Clement, H. W.; Hoinkes, A.; 
Hopt, U. T.; Schulz, E.; Krieg, J. C.; Dobschutz, E. Effects of 
antipsychotics and vitamin C on the formation of reactive oxygen 
species. J Psychopharmacol. 2010, 24 (10), 1499-1504. 
 135.  Eroglu, S.; Pandir, D.; Uzun, F. G.; Bas, H. Protective role of vitamins C 
and E in diclorvos-induced oxidative stress in human erythrocytes 
in vitro. Biol Res. 2013, 46 (1), 33-38. 
 136.  Atkinson, D. E.; Fall, L. Adenosine triphosphate conservation in 
biosynthetic regulation. Escherichia coli 





 137.  Lin, H. Z.; Yang, S. Q.; Chuckaree, C.; Kuhajda, F.; Ronnet, G.; Diehl, A. 
M. Metformin reverses fatty liver disease in obese, leptin-deficient 
mice. Nat. Med. 2000, 6 (9), 998-1003. 
 138.  Martins, P. J.; Haas, M.; Obici, S. Central nervous system delivery of the 
antipsychotic olanzapine induces hepatic insulin resistance. 
Diabetes. 2010, 59 (10), 2418-2425. 
 139.  Kast, R. E.; Karpel-Massler, G.; Halatsch, M. E. Can the therapeutic 
effects of temozolomide be potentiated by stimulating AMP-
activated protein kinase with olanzepine and metformin? Br J 
Pharmacol. 2011, 164 (5), 1393-1396. 
 140.  Kim, S. F.; Huang, A. S.; Snowman, A. M.; Teuscher, C.; Snyder, S. H. 
Antipsychotic drug-induced weight gain mediated by histamine H1 
receptor-linked activation of hypothalamic AMP-kinase. Proc Natl 
Acad Sci U S A. 2007, 104 (9), 3456-3459. 
 141.  Meltzer, H. Y. Illuminating the molecular basis for some antipsychotic 
drug-induced metabolic burden. Proc Natl Acad Sci U S A. 2007, 
104 (9), 3019-3020. 
 142.  Boyle, J. G.; Salt, I. P.; McKay, G. A. Metformin action on AMP-activated 
protein kinase: a translational research approach to understanding 
a potential new therapeutic target. Diabet. Med. 2010, 27 (10), 
1097-1106. 
 143.  Housel, A. K.; Waterbury, N.; Argo, T. R. Can metformin or rosiglitazone 
reduce metabolic side effects associated with atypical 
antipsychotics? Issues Ment Health Nurs. 2009, 30 (12), 803-805. 
 144.  Kimball, S. R. Interaction between the AMP-activated protein kinase and 
mTOR signaling pathways. Med Sci Sports Exerc. 2006, 38 (11), 
1958-1964. 
 145.  Rosner, M.; Fuchs, C.; Siegel, N.; Valli, A.; Hengstschläger, M. Functional 
interaction of mammalian target of rapamycin complexes in 
regulating mammalian cell size and cell cycle. Hum Mol Genet. 
2009, 18 (17), 3298-3310. 
 146.  Blanchard, P. G.; Festuccia, W. T.; Houde, V. P.; St-Pierre, P.; Brule, S.; 
Turcotte, V.; Cote, M.; Bellmann, K.; Marette, A.; Deshaies, Y. 
Major involvement of mTOR in the PPARgamma-induced 
stimulation of adipose tissue lipid uptake and fat accretion. J Lipid 
Res. 2012, 53 (6), 1117-1125. 
 147.  Shah, O. J.; Wang, Z.; Hunter, T. Inappropriate activation of the 




resistance, and cell survival deficiencies. Curr Biol. 2004, 14 (18), 
1650-1656. 
 148.  Jansson, N.; Rosario, F. J.; Gaccioli, F.; Lager, S.; Jones, H. N.; Roos, S.; 
Jansson, T.; Powell, T. L. Activation of placental mTOR signaling 
and amino acid transporters in obese women giving birth to large 
babies. J Clin Endocrinol Metab. 2013, 98 (1), 105-113. 
 149.  Hoeffer, C. A.; Klann, E. mTOR signaling: At the crossroads of plasticity, 
memory and disease. Trends Neurosci. 2010, 33 (2), 67-75. 
 150.  Siuta, M. A.; Robertson, S. D.; Kocalis, H.; Saunders, C.; Gresch, P. J.; 
Khatri, V.; Shiota, C.; Kennedy, J. P.; Lindsley, C. W.; Daws, L. C.; 
Polley, D. B.; Veenstra-Vanderweele, J.; Stanwood, G. D.; 
Magnuson, M. A.; Niswender, K. D.; Galli, A. Dysregulation of the 
norepinephrine transporter sustains cortical hypodopaminergia and 
schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol. 
2010, 8 (6), e1000393. 
 151.  Bou Khalil, R. Is there any place for macrolides in mood disorders? Med 
Hypotheses. 2012, 78 (1), 86-87. 
 152.  Cusin, C.; Hilton, G. Q.; Nierenberg, A. A.; Fava, M. Long-term 
maintenance with intramuscular ketamine for treatment-resistant 
bipolar II depression. Am J Psychiatry. 2012, 169 (8), 868-869. 
 153.  Sienaert, P.; Lambrichts, L.; Dols, A.; De Fruyt, J. Evidence-based 
treatment strategies for treatment-resistant bipolar depression: a 
systematic review. Bipolar Disord. 2013, 15 (1), 61-69. 
 154.  Nguyen, T.; Nioi, P.; Pickett, C. B. The Nrf2-antioxidant response element 
signaling pathway and its activation by oxidative stress. J Biol 
Chem. 2009, 284 (20), 13291-13295. 
 155.  Surh, Y. J.; Kundu, J. K.; Na, H. K. Nrf2 as a master redox switch in 
turning on the cellular signaling involved in the induction of 
cytoprotective genes by some chemopreventive phytochemicals. 
Planta Med. 2008, 74 (13), 1526-1539. 
 156.  Zhang, D. D.; Hannink, M. Distinct cysteine residues in Keap1 are 
required for Keap1-dependent ubiquitination of Nrf2 and for 
stabilization of Nrf2 by chemopreventive agents and oxidative 
stress. Mol Cell Biol. 2003, 23 (22), 8137-8151. 
 157.  Yamamoto, T.; Suzuki, T.; Kobayashi, A.; Wakabayashi, J.; Maher, J.; 
Motohashi, H.; Yamamoto, M. Physiological significance of reactive 
cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell 




 158.  Rushmore, T. H.; Morton, M. R.; Pickett, C. B. The antioxidant responsive 
element. Activation by oxidative stress and identification of the DNA 
consensus sequence required for functional activity. J Biol Chem. 
1991, 266 (18), 11632-11639. 
 159.  Purdom-Dickinson, S. E.; Sheveleva, E. V.; Sun, H.; Chen, Q. M. 
Translational control of nrf2 protein in activation of antioxidant 
response by oxidants. Mol Pharmacol. 2007, 72 (4), 1074-1081. 
 160.  Shibata, T.; Saito, S.; Kokuba, A.; Suzuki, T.; Yamamoto, M.; Hirohashi, S. 
Global downstream pathway analysis reveals a dependence of 
oncogenic NF-E2-related factor 2 mutation on the mTOR growth 
signaling pathway. Cancer Res. 2010, 70 (22), 9095-9105. 
 161.  Liby, K. T.; Sporn, M. B. Synthetic oleanane triterpenoids: multifunctional 
drugs with a broad range of applications for prevention and 
treatment of chronic disease. Pharmacol Rev. 2012, 64 (4), 972-
1003. 
 162.  Lepping, P.; Sambhi, R. S.; Whittington, R.; Lane, S.; Poole, R. Clinical 
relevance of findings in trials of antipsychotics: systematic review. 
Br J Psychiatry. 2011, 198 (5), 341-345. 
 163.  Komossa, K.; Rummel-Kluge, C.; Hunger, H.; Schmid, F.; Schwarz, S.; 
Duggan, L.; Kissling, W.; Leucht, S. Olanzapine versus other 
atypical antipsychotics for schizophrenia. Cochrane Database Syst 
Rev. 2010, (3), CD006654. 
 164.  Guertin, D. A.; Sabatini, D. M. The pharmacology of mTOR inhibition. Sci 
Signal. 2009, 2 (67), e24. 
 165.  Krause, U.; Bertrand, L.; Hue, L. Control of p70 ribosomal protein S6 
kinase and acetyl-CoA carboxylase by AMP-activated protein 
kinase and protein phosphatases in isolated hepatocytes. Eur J 
Biochem. 2002, 269 (15), 3751-3759. 
 166.  Oh, K. J.; Park, J.; Lee, S. Y.; Hwang, I.; Kim, J. B.; Park, T. S.; Lee, H. J.; 
Koo, S. H. Atypical antipsychotic drugs perturb AMPK-dependent 
regulation of hepatic lipid metabolism. Am J Physiol Endocrinol 
Metab. 2011, 300 (4), E624-E632. 
 167.  Ma, D.; Chan, M. K.; Lockstone, H. E.; Pietsch, S. R.; Jones, D. N.; Cilia, 
J.; Hill, M. D.; Robbins, M. J.; Benzel, I. M.; Umrania, Y.; Guest, P. 
C.; Levin, Y.; Maycox, P. R.; Bahn, S. Antipsychotic treatment 
alters protein expression associated with presynaptic function and 
nervous system development in rat frontal cortex. J Proteome. Res. 




 168.  He, Y.; Yu, Z.; Giegling, I.; Xie, L.; Hartmann, A. M.; Prehn, C.; Adamski, 
J.; Kahn, R.; Li, Y.; Illig, T.; Wang-Sattler, R.; Rujescu, D. 
Schizophrenia shows a unique metabolomics signature in plasma. 
Transl. Psychiatry. 2012, 2:e149. doi: 10.1038/tp.2012.76., e149. 
 169.  van der Heijden, F. M.; Tuinier, S.; Fekkes, D.; Sijben, A. E.; Kahn, R. S.; 
Verhoeven, W. M. Atypical antipsychotics and the relevance of 
glutamate and serotonin. Eur Neuropsychopharmacol. 2004, 14 (3), 
259-265. 
 170.  Cooper, A. J. Role of glutamine in cerebral nitrogen metabolism and 
ammonia neurotoxicity. Ment Retard. Dev Disabil. Res Rev. 2001, 7 
(4), 280-286. 
 171.  Yudkoff, M.; Daikhin, Y.; Horyn, O.; Nissim, I.; Nissim, I. Ketosis and brain 
handling of glutamate, glutamine, and GABA. Epilepsia. 2008, 49 
Suppl 8:73-5. doi: 10.1111/j.1528-1167.2008.01841.x., 73-75. 
 172.  Bak, L. K.; Schousboe, A.; Waagepetersen, H. S. The glutamate/GABA-
glutamine cycle: aspects of transport, neurotransmitter homeostasis 
and ammonia transfer. J Neurochem. 2006, 98 (3), 641-653. 
 173.  McKenna, M. C. The glutamate-glutamine cycle is not stoichiometric: fates 
of glutamate in brain. J Neurosci. Res. 2007, 85 (15), 3347-3358. 
 174.  Javitt, D. C. Glutamate as a therapeutic target in psychiatric disorders. Mol 
Psychiatry. 2004, 9 (11), 984-97, 979. 
 175.  Patti, M. E.; Brambilla, E.; Luzi, L.; Landaker, E. J.; Kahn, C. R. 
Bidirectional modulation of insulin action by amino acids. J Clin 
Invest. 1998, 101 (7), 1519-1529. 
 176.  Tato, I.; Bartrons, R.; Ventura, F.; Rosa, J. L. Amino acids activate 
mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt 
signaling. J Biol Chem. 2011, 286 (8), 6128-6142. 
 177.  Dominguez-Jimenez, J. L.; Puente-Gutierrez, J. J.; Pelado-Garcia, E. M.; 
Cuesta-Cubillas, D.; Garcia-Moreno, A. M. Liver toxicity due to 
olanzapine. Rev Esp Enferm Dig. 2012, 104 (11), 617-618. 
 178.  Kobayashi, A.; Kang, M. I.; Watai, Y.; Tong, K. I.; Shibata, T.; Uchida, K.; 
Yamamoto, M. Oxidative and electrophilic stresses activate Nrf2 
through inhibition of ubiquitination activity of Keap1. Mol Cell Biol. 
2006, 26 (1), 221-229. 
 179.  Huang, J.; Tabbi-Anneni, I.; Gunda, V.; Wang, L. Transcription factor Nrf2 




metabolism. Am J Physiol Gastrointest. Liver Physiol. 2010, 299 
(6), G1211-G1221. 
 180.  Kitteringham, N. R.; Abdullah, A.; Walsh, J.; Randle, L.; Jenkins, R. E.; 
Sison, R.; Goldring, C. E.; Powell, H.; Sanderson, C.; Williams, S.; 
Higgins, L.; Yamamoto, M.; Hayes, J.; Park, B. K. Proteomic 
analysis of Nrf2 deficient transgenic mice reveals cellular defence 
and lipid metabolism as primary Nrf2-dependent pathways in the 
liver. J Proteomics. 2010, 73 (8), 1612-1631. 
 181.  Serwer, L.; Hashizume, R.; Ozawa, T.; James, C. D. Systemic and local 
drug delivery for treating diseases of the central nervous system in 
rodent models. J Vis. Exp. 2010, (42), 1992. 
 182.  Edwards, S.; Koob, G. F. Experimental psychiatric illness and drug abuse 
models: from human to animal, an overview. Methods Mol Biol. 
2012, 829:31-48. doi: 10.1007/978-1-61779-458-2_2., 31-48. 
 183.  Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug 
metabolism/transport by xenobiotics. Arch Pharm. Res. 2005, 28 
(3), 249-268. 
 184.  Um, S. H.; D'Alessio, D.; Thomas, G. Nutrient overload, insulin resistance, 
and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006, 3 (6), 
393-402. 
 185.  Thimmulappa, R. K.; Mai, K. H.; Srisuma, S.; Kensler, T. W.; Yamamoto, 
M.; Biswal, S. Identification of Nrf2-regulated genes induced by the 
chemopreventive agent sulforaphane by oligonucleotide 
microarray. Cancer Res. 2002, 62 (18), 5196-5203. 
 186.  Harris, R. B. Is leptin the parabiotic "satiety" factor? Past and present 
interpretations. Appetite. 2013, 61 (1), 111-118. 
 187.  Waring, W. S.; Wrate, J.; Bateman, D. N. Olanzapine overdose is 











4EBP1  eukaryotic translation initiation factor 4E binding protein 1 
Acly   ATP citrate lyase 
Akt   protein kinase B 
ALT   alanine aminotransferase 
AMPK  AMP-activated protein kinase 
AST   aspartate aminotransferase 
CNS   central nervous system 
Cpt1a   carnitine palmitoyltransferase 1a 
DEXA   dual-energy x-ray absorptiometry 
Fasn   fatty acid synthase 
FCCP   carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
Gck   glucokinase 
Glut1   glucose transporter type 1 
Glut4   glucose transporter type 4 




H&E   hematoxylin and eosin 
HDL   high-density lipoprotein 
HFD   high-fat diet; TD.88137 Adjusted Calories diet 
LAT1   L-type amino acid transporter 1 
LDL   low-density lipoprotein 
LFD   low-fat diet; TD.08485 Low-Fat Control Diet 
MTBSTFA  N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide 
mTOR  mammalian target of rapamycin 
NAFLD  non-alcoholic fatty liver disease 
NASH   non-alcoholic steatohepatitis 
NEFA   non-esterified fatty acids 
OCR   oxygen consumption rate 
OGTT   oral glucose tolerance test 
OLZ   olanzapine 
p70S6K  70 kDa ribosomal protein s6 kinase 
Pck1   phosphoenolpyruvate carboxykinase 1 
PAS   periodic acid-Schiff reagent 
PPR   proton production rate 




SLC38A2  solute carrier family 38 member 2 
SNAT2  system A amino acid transporter 2 
Srebf1  sterol regulatory element binding protein 1 
TBDMSCI  tert-butyldimethylchlorosilane 
TG   triglycerides 










St. John’s University   B.S.   2006 
      Funeral Services 
American Academy McAllister Institute A.Occup.Studies 2006 
      Funeral Services 
University of Louisville   M.S.   2011 
Pharmacology and Toxicology 
 
Academic and Professional Experience 
2008-2010  Graduate research fellow, University of Louisville 
2010-present  NIEHS T32 predoctoral fellow, University of Louisville 




Membership in Professional Societies 
2010-2012  New York Academy of Sciences 
2010-present  Kentucky Academy of Science 
2011-present  Ohio Valley Society of Toxicology 
2011-present  Society of Toxicology 
 
Organization of Scientific Conferences, Workshops, Symposia, etc. 
Organizer, OVSOT Summer Student/Post-Doc Meeting, Louisville, KY  
08/11/11, Dept. of Pharmacology and Toxicology and Ohio Valley Society  
of Toxicology 
 
Service to the School of Medicine and/or the University 
2010-2011 University of Louisville Academic Grievance Committee 
 
Service to the Profession 
See also sections above 
2011 Organizer, OVSOT Summer Student/Post-Doc Meeting  
2011-2012 Graduate student representative, Executive Council of 





Awards and Honors 
2002-2006 Merit scholarship, St. John’s University 
2002-2006 Dean’s list, St. John’s University 
2003  Phi Eta Sigma Honor Society 
2006  Mu Sigma Alpha Honor Society 
2006 Graduation with Distinction (cum laude), St. John’s 
University 
2006 Graduation with Distinction (summa cum laude), American 
Academy McAllister Institute 
2006 Board of Trustees Award, American Academy McAllister 
Institute 
2008-2010 Graduate research fellowship recipient, Integrated Program 
in Biomedical Sciences (IPIBS) 
2010 Selected for platform presentation, Ohio Valley Society of 
Toxicology (OVSOT) 
2010 Award for platform presentation, 1st place, OVSOT annual 
meeting 
2011-2013 NIEHS T32 pre-doctoral fellowship recipient 
2011  Travel award, SOT 




2012  Travel award, SOT 
2012 President’s choice award, American Association for the 
Study of Liver Diseases annual meeting  
 
Bibliography  
A.  Published abstracts  
1. Baldauf KJ, Schmidt RH, Ding X, Beier JI, Tan M, Arteel GE (2010) 
Sulforaphane enhances liver regeneration after partial hepatectomy in mice. 
Hepatology 52:617A 
2. Tan M, Schmidt RH, Beier JI, Zhong H, States JC, Arteel GE 
(2011) Chronic low dose arsenic exposure enhances hepatic injury induced by 
high fat diet in mice. The Toxicologist 120:429 
3. Massey VL, Beier JI, Schmidt R, Zhong H, Arteel GE (2011) 
Integrin inhibitor cycloRGDfV blunts enhanced LPS-induced liver injury caused 
by ethanol in mice. Hepatology 54:970A 
4. Schmidt RH, Falkner KC, Beier J, Arteel G (2011) Sulforaphane 
prevents acetaminophen-induced hepatic injury in mice. The Toxicologist 120:99 
5. Schmidt RH, Tan M, Jokinen J, Massey VL, Zhong H, Arteel GE 
(2012) Arsenic enhances experimental liver disease via altering GI tract function: 




6. Schmidt R, Tan M, Zhong H, Arteel G (2012) Sulforaphane 
prevents liver injury caused by high-fat diet and olanzapine. The Toxicologist 
126:78 
 
B.  Papers 
1. Tan M, Schmidt RH, Beier JI, Watson WH, Zhong H, States JC, 
Arteel GE (2011) Chronic subhepatotoxic exposure to arsenic enhances hepatic 
injury caused by high fat diet in mice. Toxicol Appl Pharmacol. 257:356-364 
2. Wei X, Shi X, Koo I, Kim S, Schmidt RH, Arteel GE, Watson WH, 
McClain C, Zhang X (2013) MetPP: A Computational Platform for 
Comprehensive Two-dimensional Gas Chromatography Time-of-flight Mass 
Spectrometry-based Metabolomics. Bioinformatics. 14:1786-1792 
3. Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, 
Beier JI, Arteel GE (2013) Olanzapine activates hepatic mammalian target of 
rapamycin (mTOR): new mechanistic insight into metabolic dysregulation with 
atypical antipsychotics. J Pharmacol Exp Ther. (In press) 
4. Shi X, Wei X, Koo I, Schmidt RH, Yin X, Zhang J, Mueller EG, Kim 
SH, Vaughn A, Arteel GE, McClain CJ, Zhang X, Watson WH (2013) 
Metabolomic analysis of the effects of chronic arsenic exposure in a mouse 




5. Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Beier JI, Arteel 
GE (2013) High-fat diet exacerbates olanzapine-induced liver injury. (Manuscript 
in preparation) 
6. Schmidt RH, Kaiser JP, Massey VL, Falkner KC, Beier JI, Arteel 
GE (2013) Sulforaphane prevents acetaminophen-induced hepatic injury in mice. 
(Manuscript in preparation) 
 
C.  Presentations 
Local/Regional 
1. Research seminar, 05/2009, “Effects of rapamycin on hepatic 
steatosis caused by ethanol”, University of Louisville, Dept. of Pharmacology and 
Toxicology, Louisville, KY. 
2. Platform session, 09/2010, “Sulforaphane prevents acetaminophen-
induced hepatic injury in mice”, Ohio Valley Society of Toxicology Annual 
Meeting, Cincinnati, OH. 
3. Poster presentation, 10/2010, “Sulforaphane prevents 
acetaminophen-induced hepatic injury in mice”, Research! Louisville, Louisville, 
KY. 
4. Oral master’s exam, 11/2010, “Sulforaphane prevents 
acetaminophen-induced liver injury in mice”, University of Louisville, Department 




5. Platform session, 09/2011, “High fat diet exacerbates olanzapine-
induced liver injury: protection by sulforaphane”, Ohio Valley Society of 
Toxicology Annual Meeting, Dayton, OH. 
6. Poster presentation, 09/2012, “Arsenic enhances experimental liver 
disease via altering GI tract function: Protection with prebiotics”, Research! 
Louisville, Louisville, KY. 
National/International 
7. Poster presentation, 03/2011, “Sulforaphane prevents 
acetaminophen-induced hepatic injury in mice”, Society of Toxicology Annual 
Meeting, Washington, DC. 
8. Poster presentation, 03/2012, “High fat diet exacerbates 
olanzapine-induced liver injury: protection by sulforaphane”, Society of 
Toxicology Annual Meeting, San Francisco, CA. 
9. Poster presentation, 11/2012, “Arsenic enhances experimental liver 
disease via altering GI tract function: Protection with prebiotics”, American 
Association for the Study of Liver Diseases Annual Meeting, Boston, MA. 
 
Grant and Fellowship Support 
2008-2010 Integrated Programs in Biomedical Sciences 
Graduate Fellowship 
2011-present NIEHS T32 – ES011564 Training Grant in 
Environmental Health 
